Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV 
Protocol  
Version 6.6 
March 1, 2017 	 Page 1	Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV 
Sponsored by: 
[CONTACT_4461] (NIAID) 
NIAID Funding Mechanism:  
U01 AI105872-01 
Pharmaceutical Support Provided by: 
[CONTACT_530280] # - not needed 
Principal Investigator/Protocol Chair: 
Timothy Schacker, MD 
NIAID Medical Monitor: 
Karin Klingman, M.D. 
DAIDS-ES Document ID: 
#[ZIP_CODE] 
Draft or Version Number: 
Version 6.6 
Day Month Year 
 01 March 2017  
This template is adapted from the ICH guidance doc ument E6 (Good Clinical Practices), Section 6. 
Confidentiality Statement 
This document is confidential and is to be distributed for review only to investigators, potential investigators, consultants, 
study staff, and applicable independent ethics committees or institutional review boards.  The contents of this document shall 
not be disclosed to others without written authorization from NIAID (or others, as applicable), unless it is necessary to obtai n 
informed consent from potential study participants. ClinicalTrials.gov: [STUDY_ID_REMOVED]
Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV 
 
Protocol Version 6.6  
March 1, 2017 	 Page 2	
  
 
Statement	 of	Compliance 	
 
This trial will be conducted in compliance with the protocol, International Conference on Harmonization Good 
Clinical Practice E6 (ICH-GCP), and the applicable regulatory requirements including U.S. Code of Federal 
Regulations applicable to clinical studies (45 CFR 46 and 21 CFR 50, 56 and 21 CFR 312), directive 
2001/20/EC on the approximation of the laws, regulations an d administrative provisions of the Member States 
relating to the implementation of good clinical practice in  the conduct of clinical trials on medicinal products for 
human use as amended by [CONTACT_56998] 2005/28/EC and NIAID Clinical Terms of Award.  All key 
personnel (all individuals responsible for the design and conduct of this study) have completed appropriate 
Human Subjects Protection Training.  
 
    
 
     
 
    
 
     
 
    
 
    
 
  
Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV 
 
Protocol Version 6.6  
March 1, 2017 	 Page 3	
  
 
Signature 	[CONTACT_3490]	1	
  The signature [CONTACT_32642], and provides the necessary assurances that this trial will be conducted according to all stipulations of the protocol, including all statements regarding confidentiality, and according to local legal and regulatory requirements and applicable U.S. federal 
regulations and ICH guidelines.     
________________________________________________________  ________________ 
Timothy W. Schacker, MD, Professor of Medicine          Date 
    
 
    
 
     
 
    
 
    
 
     
 
Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV 
 
Protocol Version 6.6  
March 1, 2017 	 Page 4	
 Signature 	[CONTACT_3490]	2	
 
The signature [CONTACT_32642], and provides the necessary 
assurances that this trial will be conducted according to all stipulations of the protocol, including all statements regarding confidentiality, and according to local legal and regulatory requirements and applicable U.S. federal 
regulations and ICH guidelines.  
Meghan Rothenberger, MD, Assistant Professor of Medicine  
Signed:___________________________________________  Date:____________________ 
 Gregory Beilman, MD , Professor of Surgery     Signed:___________________________________________  Date:____________________ 
 Jeffrey Chipman, MD, Associate Professor of Surgery   Signed:___________________________________________  Date:____________________ 
 Cavan Reilly, PhD, Associate Professor of Biostatistics   Signed:___________________________________________  Date:____________________ 
 Jason Baker, MD, Assistant Professor of Medicine    Signed:___________________________________________  Date:____________________ 
 Brian Fife, PhD, Assistant Professor of Medicine    
Signed:___________________________________________  Date:____________________ 
 
Courtney Fletcher, PharmD, Dean and Professor of Pharmacy  Signed:___________________________________________  Date:____________________ 
 Daniel Douek, MD, PhD, Head, Human Immunology, VRC, NIH  
Signed:___________________________________________  Date:____________________ 
 
Richard Koup, MD, Chief, Immunology Laboratory, VRC, NIH  Signed:___________________________________________  Date:____________________ 
 
Jacob Estes, PhD, Head, Tissue Analysis Core Aids and Cancer Virus Program, NCI, NIH   
Signed:___________________________________________  Date:____________________ 
  
  
 
 
   
 
 
Reversing Tissue Fibrosis to Improve  Immune Reconstitution in HIV 
 
Protocol Version 6.[ADDRESS_688638] of Abbreviations and Ac ronyms ............................................................................................ .............................................. 8  
Protocol Summary .............................................................................................................. ..................................................... 10  
1. KEY ROLES ..................................................................................................................... ................................................ 12  
2. BACKGROUND INFORMATION AND SCIENTIFIC RATIONALE .................................................................................. 14  
2.1 Background In formation ........................................................................................................ .................................................... 14  
2.2 Study Hypothesis and Rationale ................................................................................................ ................................................ 15  
2.3 MRI Sub- study ................................................................................................................. .......................................................... 16  
2.4 Potential Risks and Benefits .................................................................................................. .................................................... 16  
  Potential Risks ............................................................................................................... .................................................... 16  
  Potential Be nefits ............................................................................................................ ................................................... 16  
3. STUDY OBJECTIVES .............................................................................................................. ....................................... 16  
3.1 Primary Ob jective ............................................................................................................. ......................................................... 16  
3.2 Secondary Ob jectives .......................................................................................................... ....................................................... 17  
3.3 Exploratory Ob jectiv es ........................................................................................................ ...................................................... 17  
4. STUDY DESIGN .................................................................................................................. ............................................ 17  
4.1 Description of th e Study Design: .............................................................................................. ................................................. 17  
4.2 Study Endpoints: .............................................................................................................. .......................................................... [ADDRESS_688639] udy Population ................................................................................................. ................................................... 18  
5.2 Inclusion/Exclus ion Criteria .................................................................................................. .................................................... [ADDRESS_688640] ........................................................................ ................................ 22  
6.3 Permitted Medications  and Procedures .......................................................................................... ............................................ 22  
6.4 Prohibited Me dications ........................................................................................................ ...................................................... 22  
7. STUDY PROCEDURES/INTERVENTIONS ................................................................................................ .................... [ADDRESS_688641] ed subjects (n=50) ..................................................................................... ........................................... 26  
  Screen ing ..................................................................................................................... ....................................................... 26  
  Baseline Visit ................................................................................................................ ..................................................... 27  
  Day 14 Visit .................................................................................................................. ..................................................... 27  
Reversing Tissue Fibrosis to Improve  Immune Reconstitution in HIV 
 
Protocol Version 6.6  
March 1, 2017 	 Page 6	
 
  Month 1 Visit ................................................................................................................. .................................................... 28  
  Months 3, 6, 9, 15, 18, 21 and 27 Visits ...................................................................................... ....................................... 28  
  Month 12 Visit ................................................................................................................ ................................................... 29  
  Month 23 Visit ................................................................................................................ ................................................... 29  
  Month 25 visit ................................................................................................................ .................................................... 29  
  Month 29.5 Visit .............................................................................................................. .................................................. 29  
 Month 30 Visit (Final Study Visit) ............................................................................................ ........................................ 29  
 Early Termina tion Visit........................................................................................................ .............................................. 29  
 Pregnancy Visit ............................................................................................................... ................................................... 29  
 Unscheduled Visits ............................................................................................................ ................................................ 29  
8.2 Schedule of Events for HIV Infected Subjects .................................................................................. ......................................... 30  
8.3 Schedule for Control - HIV Un infected Subjects (n=5) .......................................................................... ................................... 31  
  Screen ing ..................................................................................................................... ....................................................... 31  
  Study Vi sit ................................................................................................................... ...................................................... 31  
8.4 Schedule for Additional 5 Control HI V Uninfected Subjects (n=5) ............................................................... ........................... 31  
  Screen ing ..................................................................................................................... ....................................................... 31  
  MRI Sub- Study ................................................................................................................. ................................................. 31  
  Study Visit(s) ................................................................................................................ ..................................................... 31  
8.5 Schedule of Events for Additional 5 Control HIV Uninfected Subjects ........................................................... ......................... 32  
9. ASSESSMENT OF SAFETY .......................................................................................................... ................................. 32  
9.1 Definition of an Adverse Event (AE) ........................................................................................... .............................................. 32  
  Basic Defi nition .............................................................................................................. ................................................... 32  
  Definition of a Serious Adverse Event (SAE ) ................................................................................... ................................. 33  
  Definition of a Suspected Unexpected  Serious Adverse Reaction (S[LOCATION_003]R) ......................................................... ........... [ADDRESS_688642]-study Adverse Event ...................................................................................................... ............................................ 33  
  Abnormal Laboratory Values .................................................................................................... ......................................... 33  
  Hospi[INVESTIGATOR_059], Prolonged Ho spi[INVESTIGATOR_059], or Surgery ........................................................................ ............................. 34  
  Anticipated Adverse Events ............................................................................................................................................... 34  
9.2 Unanticipated Problems ............................................................................................................................................................. 34  
9.3 Recording and Docume ntation of AEs............................................................................................. .......................................... 35  
  Scales Used to Grade Seve rity of Adve rse Events ............................................................................................................. 35  
  Scales Used to Attrib ute Adverse Events ........................................................................................................................... 35  
  Analysis/Man agement ........................................................................................................... ............................................. 36  
9.4 Reporting Pr ocedures .......................................................................................................... ....................................................... 36  
  AEs to be Reported ............................................................................................................ ................................................ 36  
  Expedited Adverse Event (E AE) Reporting to DAIDS ..................................................................................................... [ADDRESS_688643] (DSMB) ....................................................................................... .............................. 41  
11. STATISTICAL CONSIDERATIONS .................................................................................................... ......................... 42  
11.1 Overview and General Design Issues............................................................................................. ............................................ 42  
11.2 Sample Size Considerations .................................................................................................... ................................................... 43  
11.3 Enrollment/Stratification/Randomization/Blinding Procedures ................................................................... .............................. 43  
11.4 Maintenance of Treatment  Randomization Codes .................................................................................. ................................... 43  
11.5 Final Analys is Plan ........................................................................................................... ......................................................... 43  
12. QUALITY CONTROL AND QUALITY ASSURANCE ......................................................................................... .......... 44 
Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV 
 
Protocol Version 6.6  
March 1, 2017 	 Page 7	
 13. ETHICS/PROTECTION OF  HUMAN SUBJECTS ........................................................................................... ............ [ADDRESS_688644]  
ISH   In situ hybridization IL  Interleukin  IR  Immune reconstitution LPS  Lipopolysaccharide 
LT  Lymphoid tissue 
MCRU  Masonic Clinical Research Unit MMP  Matrix metalloprotease MT  Microbial translocation µL  Microlitre mL   Milliliter  
MRE  Magnetic Resonance Elastography 
PB  Peripheral blood PBMC  Peripheral blood mononuclear cell PCR   Polymerase chain reaction  PI   [INVESTIGATOR_530227] 6.6  
March 1, 2017 	 Page 9	
 po  per os 
QA  Quality assurance QIA  Qualitative image analysis RNA  Ribonucleic acid 
SAE   Serious adverse event  
sCD14  Soluble CD14 SIV  Simian immunodeficiency virus 
TGF-β   Transforming growth factor beta 
TUNEL Terminal deoxynucleotidyl transferase dUTP nick end labeling  
TNF  Tumor necrosis factor  TZ  T-cell zone Treg   Regulatory T cell UMMC  University of Minnesota Medical Center VL  Viral load 
Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV 
 
Protocol Version 6.6  
March 1, 2017 	 Page 10	
 Protocol	 Summary 	
 
  
Full Title Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV 
 
Conducted By [CONTACT_4461] (NIAID) 
 
Principal Investigator [INVESTIGATOR_530228], MD 
Professor of Medicine 
University of Minnesota, Department of Medicine  
Sample Size 50 HIV infected subjects and 10 HIV uninfected control subjects.   
 
Study Population HIV infected: Inclusion: Healthy, HIV-1 positive men and women 18 years of age, 
with CD4 count 200-650cells/µl, on stable antiretroviral therapy (ART). Exclusion: 
Pregnancy, use of drugs that suppress or enhance immune function, current use of 
angiotensin converting enzyme inhibitor (ACEi) or angiotensin-2 receptor blocker (ARB). 
HIV uninfected: Inclusion: Healthy, 18 years of age. Exclusion: Pregnancy, use of 
drugs that suppress or enhance immune function, current use ACEi or ARB. 
 
Accrual Period 14 months  
Study Design This is a single-center, double-blinded, placebo-controlled study of HIV infected, 
ART treated subjects randomized 1:1 to daily losartan or placebo for 30 months. All HIV infected subjects will undergo biopsies of inguinal lymph node (LN) and gut 
associated lymphatic tissue (GALT) at baseline, [ADDRESS_688645] quarterly throughout the study and an intensive blood pharmacokinetic (PK) study will be conducted at month 1. All HIV infected subjects will be vaccinated wi th the quadrivalent hum an papi[INVESTIGATOR_530229] 
(HPV) vaccine at months 23, [ADDRESS_688646] biopsy at one time point only.    
Sub-study-MRI   10 HIV+ subjects will be randomly selected to participate in the MRI sub-study and the [ADDRESS_688647] is enrolled. 
Study Agent/Intervention 
Description Losartan 100 mg daily (starting at 50 mg and dose escalating to tolerance) vs. 
Placebo 
 
For the five additional controls: Stribild – 150 mg elvitegravir/150 mg cobicistat/200 mg emtricitabine/300 mg tenofivir disoproxil fumarate once daily and Prezista – 
[ADDRESS_688648] of losartan on lymphoid tissue (LT) fibrosis as determined by [CONTACT_530281] (FRCn).   
Secondary Endpoints 1. Impact of losartan on immune reconstitution and T cell function. 
2. Impact of losartan on immune activation. 3. Impact of losartan on HIV viral reservoir size.  4. Determination of potential drug-drug interactions between losartan and ART.  
 
Exploratory Endpoints 1. Assess the impact of losartan on frequency of dendritic cell and CD4 T-cell 
interactions with the FRCn using two-photon microscopy. Given that this is an 
exploratory endpoint, we will perform these assays in a subset of subjects (5 
losartan treated, 2 placebo treated, and 10 HIV uninfected controls).  
2. To develop methods to image collagen content of inguinal lymph nodes using 
MRI 
3. To measure drug levels and pharmacokinetic (PK) profile of antiretrovirals in 
lymph tissues of HIV uninfected people. 
 
  
  
Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV 
 
Protocol Version 6.6  
March 1, 2017 	 Page 12	
 1. KEY	ROLES		
Principal Investigator: [INVESTIGATOR_530228], M.D. 
 Professor of Medicine 
 University of Minnesota 
 Department of Medicine  [ADDRESS_688649] SE  Minneapolis, MN [ZIP_CODE]  Phone: [PHONE_10968] 
 Facsimile: [PHONE_10969] 
 [EMAIL_2504] 
 Clinical 
Co-Investigators: University of Minnesota (UMN) 
 Meghan Rothenberger, M.D. Gregory Beilman, M.D. 
 Assistant Professor of Medicine Professor of Surgery 
 
 Jeffrey Chipman, M.D. Alexander Khoruts, M.D. 
 Associate Professor of Surgery Associate Professor of Medicine 
   
 Hennepin County Medical Center (HCMC) 
 Jason Baker, M.D. 
 Assistant Professor of Medicine 
 
 Mayo Medical School  
 Andrew Badley, M.D. Nathan Cummins, M.D. 
 Professor of Medicine Assistant Professor of Medicine 
 Clinical Sites: UMN Masonic Clinical Research Unit (MCRU) 
 Masonic 211B 
 [ADDRESS_688650] SE 
 Minneapolis, MN [ZIP_CODE] 
 Phone: [PHONE_10970] 
  HCMC, Positive Care Center (PCC) 
 Blue Building, Level 1 (B1.290) 
 [ADDRESS_688651] 
 Minneapolis, MN 
 Phone: [PHONE_10634] 
 Clinical Laboratories: UMMC-Fairview Laboratory 
 [ADDRESS_688652] SE 
 Minneapolis, MN [ZIP_CODE] 
  HCMC Clinical/Anatomic Laboratories 
 [ADDRESS_688653] 
 Minneapolis, MN [ZIP_CODE] 
 Research Laboratories: Timothy Schacker, M.D.  2-[ADDRESS_688654] SE 
 University of Minnesota 
Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV 
 
Protocol Version 6.6  
March 1, 2017 	 Page 13	
  Minneapolis, MN [ZIP_CODE] 
  
 Courtney Fletcher, M.D. and Yazen Alnouti, Ph.D. 
 University of Nebraska Medical Center 
 College of Pharmacy 
 Antiviral Pharmacology Laboratory 
 986045 Nebraska Medical Center, Room 4005/4007 
 Omaha, NE [ZIP_CODE] 
 
 Daniel Douek, M.D., Ph.D. 
 National Institute of Allergy and Infectious Diseases (NIAID) 
 Vaccine Research Center 
 Human Immunology Section 
 Building 40, Room [ADDRESS_688655] Koup, M.D.  National Institute of Allergy and Infectious Diseases (NIAID) 
 Vaccine Research Center 
 Immunology Laboratory  [ADDRESS_688656]  Building 40, Room 4500  Bethesda, MD [ZIP_CODE] 
 
Biostatistician: Cavan Reilly, Ph.D. 
 Associate Professor of Biostatistics  University of Minnesota  Biostatistics, Division of SPH 
 Mayo A460 
 [ADDRESS_688657] SE  Minneapolis, MN [ZIP_CODE]   
Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV 
 
Protocol Version 6.6  
March 1, 2017 	 Page 14	
 2. BACKGROUND 	INFORMATION 	AND	SCIENTIFIC 	RATIONALE 	
2.1 Background 	Information 	
The goal of combination antiviral therapy (cART) in HIV is to suppress viral replication and restore immune 
function.  It is possible with modern cART to suppress plasma viremia to below detectable limits in most people; however immune reconstitution (IR) is often incomplete, and significant immunologic abnormalities persist, even after years of therapy.  CD4 T cell populations in peripheral blood mononuclear cells (PBMC), lymph node (LN), and gut associated ly mphoid tissue (GALT) do not reconstitute to normal levels [1-4], 
responses to vaccines remain abnormal [5-8], and life expectancy continues to be significantly decreased compared to age-matched controls [9].  The underlying mechanisms driving these persistent immune abnormalities are likely related to the fact that markers of immune activation (IA) do not normalize in treated patients [10-12]. Indeed, there is growing evidence to s upport a model of persistent IA during therapy driving 
disease progression, albeit at a much slower rate than in untreated patients.  
Causes of persistent IA before and during therapy include ongoing virus production [13], co-infections such 
as cytomegalovirus (CMV) [14], and microbial translocati on (MT) of bacterial products across a persistently 
damaged gut epi[INVESTIGATOR_2130] [12, 15, 16].  IA inevitably leads to pathologic changes in lymphoid tissues (LT) that significantly alter their function and limit immune recons titution (IR). The primary pathology of persistent IA 
in LT is collagen deposition in the parafollicular T-cell zone (TZ) of secondary LN and GALT that gradually 
destroys TZ structure [17, 18].  Collagen deposition is m ediated by [CONTACT_530282] (TGF-ß) 
that is made by [CONTACT_30962] T cells (Treg) recruited into LT in an attempt to control virus production [19-21].  
During chronic and treated infection, when virus production is either substantially or completely suppressed, co-infections and MT may play a larger role in TGF-ß production.  Irrespective of the cause, TZ collagen accumulates over time and leads to depletion of naive and central memory (CM) CD4 T cells and prevents 
IR when cART is begun [17, 22].  Collagen destroys the fibroblastic reticular cell network (FRCn) which is a 
mesh of hollow fibers that form the skeletal anatomy of the TZ [23].  T cells require contact [CONTACT_530283]7 (made by [CONTACT_530284]) required for survival [24-26].  Collagen formation in the TZ is a cause of naive and CM depletion and prevents their full reconstitution when cART is begun.  Thus TZ collagen plays a critical role in HIV pathogenesis, and therapi[INVESTIGATOR_530230] y be an important adjunctive therapy to improve 
IR. 
 
We have used the TGF-ß inhibitor pi[INVESTIGATOR_530231] a non-hum an primate model of LT fibrosis induced by [CONTACT_530285].  Pi[INVESTIGATOR_530232] a drug licensed outside of the U.S. for the treatment of idiopathic pulmonary fibrosis (IPF) and it blocks TGF-ß at the level of phosphorylati on of SMAD 2,[ADDRESS_688658] [27-
34].  We show that animals receiving pi[INVESTIGATOR_530233], a more 
normal FRCn and significantly greater numbers of CD4 T cells in PBMC and LN.  Pi[INVESTIGATOR_530234].  However, an alternative drug exists that may be superior to pi[INVESTIGATOR_7735].  Losartan is an FDA-approved angiotensin receptor inhibitor (ARB) that inhibits TGF-ß at the level of phospho rylation of SMAD 2,3 [35-38] with animal and human 
studies to show it reverses existing fibrosis in lung, liver, and kidney [39-43].  It is widely used throughout 
the world in Marfan syndrome for its antifibrotic properties.  Importantly, distinct from pi[INVESTIGATOR_7735], losartan 
also decreases inhibitors of matrix metalloproteases that prevent tissue remodeling and increases proteases 
that induce tissue remodeling [39, 44, 45].  Further, it has anti-inflammatory properties that may be uniquely beneficial in the context of HIV infection.  It inhibits LPS-induced inflammatory signaling, an important component of MT, and decreases levels of tumor necrosis factor (TNF), IL6, and soluble adhesion molecules [46, 47]. 
   
Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV 
 
Protocol Version 6.6  
March 1, 2017 	 Page 15	
 2.2 Study	Hypothesis 	and	Rationale	
Our hypothesis is that treatment of HIV infected subjects with losartan, which has specific anti-inflammatory 
and anti-fibrotic actions will: 1) reverse existing fibrosis, 2) restore LN architecture, 3) increase the number and improve the function of peripheral and lymphatic CD4 T cells, 4) decrease levels of IA, 5) decrease HIV reservoirs, and 5) be safe and well tolerated.  To address this hypothesis, we will enroll HIV infected 
subjects and randomize them 1:1 to losartan vs placebo, then serially sample blood and LT.  In similar 
longitudinal tissue biopsy protocols our drop-out rate has ranged from 20-25%.  Therefore, we plan to enroll [ADDRESS_688659] 50 complete the protocol.  All HIV infected subjects randomized to losartan will initiate therapy at a dose of 50 mg per os (po) daily and increase the dose to [ADDRESS_688660] of losartan in patients with Marfan syndrome [48].  Given risk of teratogenicity with losartan, all female subjects of reproductive age who are enrolled in the protocol will be required to use a reliable and effective method of contraception for the duration of the study. Lymphatic tissue biopsies for primary endpoint analysis will be obtained at baseline and 12 and 30 months after initiation of losartan or placebo. We are following subjects for 30 
months because we felt that a long period of follow up may be required to discern a significant difference in 
the treatment groups given the persistence of LT fibr osis in subjects treated with ART alone (unpublished 
data).  HIV infected subjects will also be administered the human papi[INVESTIGATOR_28597] (HPV) quadrivalent vaccine 
(Gardasil) per the manufacturer’s recommended dosing schedule to assess immune response (a secondary endpoint).  Gardasil vaccine is FDA-approved for use in men and women ages 9 to 26 to prevent the 
complications related to infection with HPV types 6, 11, 16 and 18.  Although not approved for adults 
>26 years of age, the vaccine has been well-studied in older populations and has been found to be safe and well-tolerated [49-51].  It is expected that many study subjects will have been exposed to 1 or more of the HPV serotypes included in the vaccine; however, bas ed on epi[INVESTIGATOR_46294], it is not expected that 
subjects will have been exposed to all 4 serotypes [52-54].  Therefore, this vaccine can be used to assess 
both neo and recall immune responses.  Vaccination will be initiated at the end of the study to maximize 
time on study drug prior to vaccination and to ensure that tissues are collected at time of maximal immune 
response.    Though there are no known or anticipated drug interactions between losartan and ARVs, this has not been extensively studied. Therefore an intensive pharmacokineti cs experiment will be cond ucted on all HIV infected 
subjects at month 1 of the study (when losartan is at steady state). In addition, levels of ARVs and losartan in plasma and PBMCs will be performed quarterly over the 30-month study period and intracellular levels of losartan and ARVs will be measured in LT at month 30. These analyses will be performed in semi real-time to ensure that subjects are not put at risk from unexpected drug-drug interactions.   We will enroll [ADDRESS_688661] shown lymph node concentrations of all ARVs to be suboptimal. No one has 
yet measured ARV concentrations in lymph nodes of healthy volunteers; we feel this is an excellent 
opportunity to answer that question. These subjects will return to the medical center for an inguinal LN 
biopsy and colonoscopy and blood draws at baseline, hours 1, 2,3,4,6,8,12 and 24 at one time point only.  The five control subjects who are taking Stribild and Prezista will be part of the MRI-sub-study (See Appendix I). This test will occur once during the two weeks while they are taking the antiretrovirals, prior to the biopsy.  
 
In addition, these negative controls are important to the success of the two-photon microscopy experiment, 
which is used to measure motility of lymphocytes on the LN FRCn.  The HIV negative control group will be 
Reversing Tissue Fibrosis to Improve  Immune Reconstitution in HIV 
 
Protocol Version 6.[ADDRESS_688662] that 10 control subjects will be adequate to establish normal motility.    
2.3 MRI	Sub‐study		
This sub-study will involve 10 regular subjects & the [ADDRESS_688663] collagen levels measured.  We think it possible 
that this non-invasive procedure m ight someday be used as a biomarker in studies of anti-fibrotic therapy in 
HIV infection. (See Appendix I for the MRI sub-study protocol). 
 
2.4 Potential 	Risks	and	Benefits 	
 
 Potential Risks 
Potential risks of study procedures (venipunctu re, inguinal LN biopsy, and colonoscopy with GALT 
biopsies) are detailed in Section 7.[ADDRESS_688664] common 
side effects of Prezista are drug –induced hepatitis, skin reactions ranging from mild to severe, use with caution with a known sulfonamide allergy, new onset diabetes or hyperglycemia, 
redistribution/accumulation of body fat or immune reconstitution syndrome and subjects with hemophilia may develop increased bleeding events, The most common side effects of Prezista include diarrhea, 
nausea, rash, headache, abdominal pain and vomiting.   
 
 Potential Benefits 
All subjects (excluding control subjects) will receive results of clinical laboratory testing and HPV vaccination at no cost over the course of this study.  There are no other direct benefits of participation for the individual subjects.  However, the proposed research has the potential to significantly benefit people infected with HIV. 
3. STUDY	OBJECTIVES 	
3.[ADDRESS_688665] of losartan on frequency of dendritic cell and CD4 T-cell interactions with the FRCn using two-photon microscopy.  2. To develop methods to image collagen content of inguinal lymph nodes using MRI 3. To measure drug levels and pharmacokinetic (PK) pr ofile of antiretrovirals in lymph tissues of HIV 
uninfected people. 
 
4. STUDY	DESIGN	
4.1 Description 	of	the	Study	Design:	
This is a randomized, double-blind, placebo-controlled trial of 50 HIV-1 infected individuals on stable ART randomized in a 1:1 ratio to losartan (50 mg orally daily titrated to 100 mg daily) vs placebo for 30 months.  We plan to enroll a total of 63 HIV infected subjects to ensure that 50 complete the protocol.  All HIV infected subjects will undergo biopsies of inguinal lymph node (LN) and gut associated lymphatic tissue (GALT) for primary endpoint analysis at baseline, [ADDRESS_688666] 
quarterly throughout the study and an intensive blood phar macokinetic (PK) study will be conducted at month 1.  
All HIV infected subjects will be vaccinated with the quadrivalent human papi[INVESTIGATOR_28597] (HPV) vaccine at 
months 23, [ADDRESS_688667] is enrolled. 
 
4.2 Study	Endpoints: 	
 Primary Endpoint 
The primary endpoint is to determine the impact of losartan on LT fibrosis in HIV infected, ART treated 
adults.  This will be determined by [CONTACT_530286] (IHC) and quantitative image analysis (QIA). 
 
 Secondary Endpoints  
There are 4 secondary endpoints:  1. We will assess the impact of losartan on immune reconstitution and T-cell function by 
[CONTACT_35755]: 
 Frequency of CD4+ T cells, TUNEL+CD3+CD8+ T cells and cells expressing TGF-beta and 
lymphotoxin-beta in LT using IHC. 
 Serum levels of IL-7 and TGF-beta using ELISA. 
 The immune response to HPV vaccination using flow cytometry to identify cells stimulated by 
[CONTACT_530287]. 
 
2.  We will determine the impact of losartan on immune activation in HIV infected, treated 
individuals by [INVESTIGATOR_16598]: 
Reversing Tissue Fibrosis to Improve  Immune Reconstitution in HIV 
 
Protocol Version 6.6  
March 1, 2017 	 Page 18	
  Frequency of activated T-cell populations (specifically CD3+CD4+CD38+, CD3+,CD8+CD38+, 
CD4+Ki67+ and CD8+Ki67+ T cells) in LT using immunofluorescence staining.  
 Percentage of activated T cells, macrophages and dendritic cells in PBMCs and LT using flow 
cytometry.  
 Intracellular levels of the inflammatory cytokines IL-17, IFNg, IL-2, TNF, IL-10, and GM-CSF in 
PBMCs and LT using cytokine staining. 
 Plasma levels of additional inflammatory markers including LPS, sCD14, I-FABP, IL-1b, IL-1RA, IL-6, 
TNF, amyloid A, CRP, and D-dimer using limulus assay (sCD14) and ELISA (all others).   
 
3.  We will assess the potential for losartan to reduce the size of the viral reservoir by 
[CONTACT_530288]+ and DNA+ cells in LN and GALT using both radiolabeled in situ hybridization (ISH) and RNAscope
TM in situ technology.  
 
4.  To ensure that losartan is safe and well tolerated when used with ART, we will: 
 Perform an intensive pharmacokinetics experiment in  all HIV infected subjects at month 1 of the study 
(when losartan is at steady state).  
 Measure levels of ARTs and losartan in plasma and PBMCs quarterly over the 30-month study period. 
 Measure intracellular levels of los artan and ARTs in LT at month 30. 
 
  Exploratory Endpoints 
1. Assess the impact of losartan on frequency of dendrit ic cell and CD4 T-cell interactions with the FRCn using 
two-photon microscopy.  
2. To develop methods to image collagen content of inguinal lymph nodes using MRI 
3. To measure drug levels and pharmacokinetic (PK) profile  of antiretrovirals in lym ph tissues of HIV uninfected 
people. 
5. STUDY	POPULATION 	
5.1 Selection	 of	Study	 Population 	
83% of persons living with HIV/AIDS in the State of Minnesota are male, 50% are white, 32% black (with 
10% being African born), 9% Hispanic/Latino, 4% American Indian, and 5% Asian or “Other” (Minnesota Department of Health 2010 data).  By [CONTACT_530289], we anticipate that the demographic profile of our study participants will represent this distribution.      HIV infected subjects will be recruited using our well-es tablished recruitment network in the Twin Cities that 
involves partnerships with local HIV clinics and co mmunity organizations such as the Minnesota AIDS 
Project.  We will also design study specific advertisements and flyers for use in local publications and 
clinics.  HIV uninfected subjects will be recruited through flyers placed around the University of Minnesota 
and advertisements in local magazines and newspapers.  As above, based on drop-out rates in similar studies we have conducted in the past, we plan to enroll a total of 63 HIV infected subjects to ensure that 50 complete the protocol.  
 
5.2 Inclusion/Exclusion 	Criteria	
 HIV infected participants: a. Inclusion Criteria:  
Participants must meet all of the following inclusion criteria to participate in this study:  
1. HIV-1 infected. 
Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV 
 
Protocol Version 6.6  
March 1, 2017 	 Page 19	
 2.  18 years of age. 
3. Baseline peripheral CD4+ T cell count 200-650 cells/mm3 for at least two measures and no more 
than one measure outside the range over the 6 months prior to study enrollment.  
4.  12 months of consistent use of antiretrovirals without disruption lasting ≥ 1 week in the period 
leading up to study enrollment.  
5. HIV viral load (VL) < 50 copi[INVESTIGATOR_014]/mL for at least two measures over the [ADDRESS_688668] be willing to use a form of effective contraception for the 
duration of the study. Effective contraception includes hormonal injection, implant or oral medication, IUD, diaphragm, or cervical cap with spermicide.  Condoms cannot be used as the sole form of contraception.  
 
b. Exclusion  Criteria: 
Participants meeting any of the following exclusion criteria at baseline will be excluded from study participation: 
1. Use of any immunomodulator within the 12 months prior to study enrollment .  An immunomodulator 
for the purposes of this study is defined as a drug known to either diminish or augment a patient’s 
immune system.  Examples of these include, but are not limited to, systemic corticosteroids (use of 
topi[INVESTIGATOR_530235]), TNF-inhibitors, rituximab, cyclophosphamide, abatacept, 
cyclosporine, azathioprine, 6-mercaptopurine, methotrexate, sulfasalazine, cyclosporine, tacrolimus, 
sirolimus, and intravenous immune globulin.  NOTE:  It is considered permissible for a potential subject 
to have 1) taken a brief ( ≤ 2 week) course of oral corticosteroids for acute respi[INVESTIGATOR_4375], 2) 
received a corticosteroid injection into a joint, and/or 3) inhaled corticosteroids for control of reactive airway disease.
 
2. Current use of an ARB or ACEi.  3. Current use of rifaximin, fluconazole or lithium given potential for drug interactions with losartan. 4. Prior reaction or intolerance to an ARB or ACEi. 5. Prior diagnosis of a chronic inflammatory disease with serologic or clinical  evidence as diagnosed by 
a primary care physician or specialist.  Examples  of these include, but are not limited to, systemic 
lupus erythematosus, rheumatoid arthritis, sc leroderma, Sjogren’s syndrome, mixed connective 
tissue disease, psoriasis, polymyositis, derma tomyositis, vasculitis, sarcoidosis, Wegener’s 
granulomatosis, giant cell arteritis, polyarteriti s nodosa, gastrointestinal pemphigoid, eosinophilic 
colitis, Crohn’s disease, ulcerative colitis, autoimmune hepatitis. 
6. Prior diagnosis of a connective tissue disease with genetic, serologic or clinical evidence as 
diagnosed by a primary care physician or specialis t. (Marfan’s syndrome, Ehlers-Danlos syndrome). 
7. Screening systolic blood pressure < 110. 8. Estimated Glomerular Filtration Rate (eGFR) of  < 30ml/min/1.[ADDRESS_688669] and/or ALT > 3 times the upper limit of normal within 60 days of study enrollment. 
10. Potassium > 5.[ADDRESS_688670] feeding. 14. Prior vaccination with an HPV vaccine, including Cervarix (GlaxoSmithKline) or Gardasil ([COMPANY_006]). 
15. History of hypersensitivity or severe allergic reactions to yeast. 16. At the principle investigator’s discretion if not a suitable surgical candidate. 17. Currently undergoing treatment for hepatitis C or treatment completed within the last 3 months 18. History of ≥ 3 previous inguinal lymph node biopsies 
 
 HIV-uninfected: 
Reversing Tissue Fibrosis to Improve  Immune Reconstitution in HIV 
 
Protocol Version 6.[ADDRESS_688671] meet all of the following inclusion criteria to participate in this study:  
1. HIV uninfected. 
2.  18 years of age. 
3. No contraindication to proposed study procedures. 
 
 b. Exclusion  Criteria 
Participants meeting any of the following exclusion criteria at baseline will be excluded from study 
participation: 
1. Use of any immunomodulator within the 12 months prior to study enrollment (as defined above). 
2. Current use of an ARB or ACEi. 3. Prior diagnosis of a chronic inflammatory dis ease with serologic or clinical evidence (as defined 
above). 
4. Prior diagnosis of a connective tissue disease with genetic, serologic or clinical evidence as 
diagnosed by a primary care physician or specialis t. (Marfan’s syndrome, Ehlers-Danlos syndrome). 
5. AST and/or ALT > 1.5 times the upper limit of normal at screen 6. At the principal investigator’s discretion if not a suitable candidate. 7. Sulfa allergy  8. Pregnancy. 
 
5.3 Co‐Enrollment 	Guidelines 	
Subjects are restricted from taking part in any other studies that involve tissue sampling or administration of 
pharmacologic agents while enrolled in this protocol.  
 
6. STUDY	AGENTS	
6.1 Study	Agent	 Acquisition 	
 Losartan 
  [IP_ADDRESS] Formulation, Packaging, and Labeling   Losartan will be provided for this study by [CONTACT_530290] (IDS) pharmacy at the University of Minnesota.  Matched placebo  
  pi[INVESTIGATOR_530236].  ID S pharmacy will maintain randomization codes and  
  will provide appropriate labels for medications distributed to subjects.  
             
            [IP_ADDRESS] Preparation, Administration, Storage, and Dosage of Study Agent(s)/Intervention(s) 
HIV infected subjects will be randomized to placebo or losartan.  Starting dose of losartan will be 
[ADDRESS_688672] of Pharmacy requirements, FDA 
guidelines, and Good Clinical Practices.   
 
[IP_ADDRESS] Study Agent Accountability Procedures 
Losartan or placebo will be distributed to subjects at baseline visit, week 2 visit and 
approximately every 3 months thereafter.  Pharmacy documents, including study drug 
accountability logs, study drug ordering/shippi[INVESTIGATOR_24068], and regulatory documents are maintained 
by [CONTACT_530291].  All handling of study agents (e.g., drug receipt and storage, drug 
Reversing Tissue Fibrosis to Improve  Immune Reconstitution in HIV 
 
Protocol Version 6.6  
March 1, 2017 	 Page 21	
 accountability, etc.) will be done by a pharmacist.  If subjects have study drug remaining at time 
of study completion or study withdrawal, designated study staff will collect the drug from the subject and return it to the UMN IDS where it will be properly disposed of.  
 Gardasil Vaccine 
  [IP_ADDRESS] Formulation, Packaging, and Labeling 
  Standard pre-filled syringes of Gardasil will be purchased commercially through [COMPANY_006] for use in 
  this study and will be shipped directly to the IDS pharmacy.               
             
[IP_ADDRESS] Preparation, Administration, Storage, and Dosage of Study Agent(s)/Intervention(s) 
Gardasil will be stored in the IDS pharmacy and will be distributed by [CONTACT_530292].  Research pharmacists and credentialed 
pharmacy technicians charged with dispensing research-related drugs will receive protocol-
specific training and are compliant with State Board of Pharmacy requirements, FDA guidelines, 
and Good Clinical Practices.  Trained study st aff will administer 0.5mL of Gardasil (which 
contains suspension of 120 mcg L1 protein from HPV types 6, 11,16, and 18) intramuscularly in 
the thigh of HIV infected subjects at months 23, 25 and 29.5.    [IP_ADDRESS] Study Agent Accountability Procedures 
Pharmacy documents, including study drug accountability logs, study drug ordering/shippi[INVESTIGATOR_530237], and regulatory documents are maintained by [CONTACT_530291].  All handling of study agents (e.g., drug receipt and storage, drug accountability, etc.) will be done by a pharmacist.  IDS will properly dispose of any product that remains when the study is completed.  
 
 Stribild 
  [IP_ADDRESS] Formulation, Packaging, and Labeling 
STRIBILD is a fixed-dose combination tablet containing elvitegravir, cobicistat, emtricitabine, and 
tenofovir DF for oral administration.  Stribild will be provided for this study by [CONTACT_530293] (IDS) pharmacy at the University 
of Minnesota.  [IP_ADDRESS]
 Preparation, Administration, Storage, and Dosage of Study Agent(s)/Intervention(s) 
HIV non-infected subjects will receive 150 mg elvitegravir/150 mg cobicistat/200 mg 
emtricitabine/[ADDRESS_688673] of Pharmacy requirements, FDA guidelines, and Good Clinical Practices  
[IP_ADDRESS] Study Agent Accountability Procedures 
Pharmacy documents, including study drug accountability logs, study drug ordering/shippi[INVESTIGATOR_530237], and regulatory documents are maintained by [CONTACT_530291].  All handling of 
study agents (e.g., drug receipt and storage, drug accountability, etc.) will be done by a 
pharmacist.  If subjects have study drug rem aining at time of study completion or study 
withdrawal, designated study staff will collect the drug from the subject and return it to the UMN IDS where it will be properly disposed of. 
 
 Prezista 
 [IP_ADDRESS] Formulation, Packaging and Labeling 
Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV 
 
Protocol Version 6.6  
March 1, 2017 	 Page 22	
 Prezista comes in tablets or oral suspension.  Prezista will be provided for this study by [CONTACT_530294] (IDS) pharmacy at the University of Minnesota.    [IP_ADDRESS] Preparation, Administration, Storage and Dosage of Study Agent(s)/Intervention(s). 
HIV non-infected subjects will receive [ADDRESS_688674] of Pharmacy requirements,  FDA guidelines, and Good Clinical Practices. 
 
[IP_ADDRESS] Study Agent Accountability Procedures 
Pharmacy documents, including study drug accountability logs, study drug ordering/shippi[INVESTIGATOR_530237], and regulatory documents are maintained by [CONTACT_530291].  All handling of study agents (e.g., drug receipt and storage, drug accountability, etc.) will be done by a 
pharmacist.  If subjects have study drug remaining at time of study completion or study 
withdrawal, designated study staff will collect the drug from the subject and return it to the UMN IDS where it will be properly disposed of. 
 
6.[ADDRESS_688675]	
Adherence to study drug (losartan or placebo) will be assessed by [CONTACT_530295] 
(these occur at least quarterly throughout the 30-month study).  Subjects will be asked to bring their pi[INVESTIGATOR_530238] a measure of adherence.  Gardasil will be administered at appropriate dosing intervals by [CONTACT_68293], ensuring proper 
adherence.  
6.3 Permitted 	Medications 	and	Procedures 	
      Medications not listed under prohibited medications and the manufacturers’ package inserts are permitted during this study. If subjects develop a condition that requires a medical procedure while on study, we will determine impact of this on study participation on a case by [CONTACT_413]. Whenever a concomitant 
medication or study agent is initiated or a dose is changed, investigators must review the concomitant 
medications and study agents’ most recent package inserts, and Investigator’s Brochures to obtain the most current information on drug interactions, contraindications, and precautions.  
 
6.4 	 Prohibited 	Medications 		
The following drugs are not permitted for HIV subjects while on study: 
o Any immunomodulator (defined as a drug known to either diminish or augment a patient’s 
immune system). Examples include, but are not li mited to, systemic corticosteroids (use of 
topi[INVESTIGATOR_530235]), TNF-inhibitors, rituximab, cyclophosphamide, abatacept, 
cyclosporine, azathioprine,  6-mercaptopurine, methotrexate, sulfasalazine, cyclosporine, 
tacrolimus, sirolimus, and intravenous immune globulin.  
o ACE inhibitors 
o ARBs other than the study drug 
o Rifampin 
o Lithium 
o Fluconazole 
 The following drugs are not permitted for uninfected control subjects while taking Stribild and Prezista: 
o Any antiretroviral drugs 
Reversing Tissue Fibrosis to Improve  Immune Reconstitution in HIV 
 
Protocol Version 6.6  
March 1, 2017 	 Page 23	
 o Any nephrotoxic drugs 
o Any drugs that are highly dependent on CYP3A for clearance and for which elevated plasma 
concentrations are associated with serious and/or life-threatening events 
 
 
 
7. STUDY	PROCEDURES/INTERVENTIONS	
7.1 Description 	and	Potential 	Risks	of	Clinical	Procedures 		
 Medical History 
At screening and baseline visits, an extensive medical history will be obtained (including prior diagnoses, medications, surgeries, etc.).  Interval medical histories will be obtained at each subsequent study visit.  Only trained designated study staff or physicians will obtain the medical history.  History will primarily be obtained by [CONTACT_232456].  If the subject is agreeable and signs a release of information form, medical records may also be obtained and reviewed by [CONTACT_530296].  
Obtaining a medical history may make subjects feel uncomfortable or embarrassed.  There are no other 
potential risks.  
 
 Physical Exam  
At screening, a physical exam will be performed which will include measurement of vital signs and evaluation of heart, lungs, abdomen, and neurologic and lym phatic systems.  At all other time points 
indicated, a targeted physical examination including measurement of vital signs and evaluation of heart, lungs, abdomen, prior LN biopsy sites, and neurologic system will be performed.  Only trained study 
staff and study physicians will perform exams.  Pe rforming a physical exam may make subjects feel 
uncomfortable or embarrassed.  There are no other potential risks.   
 Medical Adherence Counseling   
At each visit, designated study staff or physicians will counsel subjects about the importance of adherence to ART and study medications.  Women of child-bearing potential will be counseled about the importance of adherence to contraceptives.  There are no potential risks associated with this.  
 
 Venipuncture  
Venipuncture will be performed at each visit and will be done only in the MCRU or Positive Care Center. Only trained research clinic staff or physicians will be allowed to perform venipuncture.  The risks of 
venipuncture are transient pain, bleeding, lightheadedness, bruising, possible vasovagal reaction, and 
infection. 
 
 Gardasil Vaccination 
Gardasil vaccine will be administered to HIV infected s ubjects at months 23, [ADDRESS_688676] a local anesthetic and make a small (5 cm) incision over the lymph node.  It will be removed and the incision closed.  This 
technique has been successfully used in over [ADDRESS_688677] will be seen immediately by [CONTACT_530297](s).    
   
 Colonoscopy with Ileal and Rectal Biopsies 
Colonoscopi[INVESTIGATOR_530239]. Alex Khoruts,  a member of the Division of 
Gastroenterology in the Department of Medicine at the University of Minnesota.  HIV infected subjects will have biopsies performed at baseline and months [ADDRESS_688678]-biopsy 
care will be given by [CONTACT_530298]. 
 
 MRI  
MRI will be performed by [CONTACT_530299], PhD, a faculty member of the Department of Radiology at the 
University of Minnesota. MRI sub-study participant s will undergo MRI one to three weeks prior to the 
baseline, Month 12 or Month 30 visit. MRI will be performed at the Center for Magnetic Resonance 
Research (CMRR) without use of contrast dye. Sub-study participants will be screened and consented prior to undergoing MRI by [CONTACT_530300]. Subjec ts will be asked to avoid eating or drinking 
anything for four hours prior to the procedure. The subject will be positioned on their back on the scanner table, will enter the magnet tunnel feet first, and will have a surface coil consisting of a flexible 
plastic sheet placed around their body and secured with Velcro. A series of scans that in total will last between 60 – 180 minutes will be performed. These scans are intended to develop new methods for acquiring and analyzing MRI data to characterize structural and functional changes of the lymphatic 
tissue between the normal and disease state. 
 
Risks of moving in/near the scanner and during the MR scanning include dizziness, warming, and 
muscle twitching. Some metallic objects are attracted to the magnet and cannot be brought into the room. Some participants may experience claustrophobia. The MR scanner makes loud noses. Some 
people report mild nausea, headache, a metallic taste in their mouth, or sensations of flashing lights that 
if present, subside shortly after leaving the magnet. There is a risk of unknown effects related to 
participation in MRI research. There are no benefits to participation. Incidental findings are not expected, but if found, a Radiologist associated with CMRR will review the MR images and will recommend the 
subject follow-up with their primary medical provider as needed.
 
See Appendix I for additional information about MRI 
 
Reversing Tissue Fibrosis to Improve  Immune Reconstitution in HIV 
 
Protocol Version 6.[ADDRESS_688679] protections.  
Study staff will comply with all related regulations and laws, included, but not limited to 45 CFR 46 and 21 
CFR 50, 56 (FDA version), and HIPAA Privacy Regulations.  Study will be conducted in accordance with US 
and international standards for good clinical practices, applicable regulations, and institutional research 
policies and procedures. 
 Subjects will be rigorously screened against inclusion/exclusi on criteria to ensure that their participation is 
safe.  All staff members responsible for taking a medical history that could potentially make the participant uncomfortable have been specifically trained for how to do this in a sensitive manner . Only qualified study or 
clinic staff or physicians will draw blood to minimize risks. Pregnancy testing will be performed at screening, 
baseline, every 3 months, and anytime during follow up when the woman or investigator suspects pregnancy.  In addition, study staff will stress the importance of adherence to contraceptives in order to minimize risks related to unintended fetal exposure. Subjects  will be closely observed for systemic adverse 
events and toxicity related to the study drug on a r outine basis through interviews, clinical assessment 
(including measuring vital signs and physical exam), and monitoring of renal function, liver function, and 
hematologic panel.  All lymph node biopsies will be perfo rmed by [CONTACT_40420]. Gregory Beilman, [CONTACT_530337], or [CONTACT_530338] who have perform ed >[ADDRESS_688680]. Alexander Khoruts who has performed 
>[ADDRESS_688681]. Fletcher’s laboratory and will 
be analyzed in semi real-time. Levels of losartan and all ARVs that an individual subject is taking will be monitored to ensure that subjects are not exposed to supr atherapeutic levels of any drug, that losartan does 
not decrease levels of any ARVs, and that the active me tabolite of losartan is within the expected range.     
Results of these analyses will be communicated to the PI [INVESTIGATOR_530240].  If losartan is found to either increase or decrease levels of a particular ARV, the IRB will be notified and all enrolled subjects taking that ARV will be contact[CONTACT_530301].  Depending on the type of drug-drug interaction, 
toxicity labs and/or HIV VL will be obtained within [ADDRESS_688682] with 
contaminated needles, blood, and blood products, appropriate blood and secretion precautions will be employed by [CONTACT_43613][INVESTIGATOR_122505], as currently recommended by [CONTACT_530302] (NIH). 
  
 Specimen Preparation, Handling and Shippi[INVESTIGATOR_530241], handling and shippi[INVESTIGATOR_007].   
 
[IP_ADDRESS]	Blood	
All blood samples taken in the MCRU and Positive Care Clinic will be immediately transferred to 
the appropriate site. Research study staff will order clinical labs (e.g. CD4 T cell count, HIV VL, CMP, and CBC) and ensure that the appropriate blood collection tubes are sent to the appropriate clinical laboratory.  Samples drawn for research purposes will be transported by a 
scientist in the Schacker lab from the MCRU to the laboratory for isolation of plasma, serum and 
PBMCs.  Research samples obtained in the Positive Care Clinic will be transported to the Schacker lab by [CONTACT_530303].  Please refer to the Specimen Management 
Plan in the study files for details regarding the distribution of serum, plasma and PBMCs to specialized laboratories for analysis.  
 
		[IP_ADDRESS]	 Inguinal 	Lymph	Node	Biopsies	
Lymph nodes will be harvested in the MCRU and immediately sectioned at the bedside by a study physician.  For HIV infected subjects, one portion will be placed into freshly made 4% 
paraformaldehyde (PFA) for 24 hours (and then transferred to 80% ethanol prior to paraffin embedding) and the other is placed into RPMI and immediately transported to the Schacker laboratory for preparation of cell suspension.  Distribution of isolated cells is detailed in the 
Specimen Management Plan. For subjects enrolled in the two-photon microscopy study, a small 
section of the LN intended for histology will be immediately transferred fresh to the Fife laboratory.  For HIV uninfected control subjects, half of the LN will be placed into fresh PFA and managed as above.  The other half will be transferred fresh to the Fife laboratory.   
 
[IP_ADDRESS]	Colonoscopy 	with	Ileal	and	Rectal	Biopsies	
Approximately 20 snip biopsies of ileum and rectum will be obtained. Half of these samples will 
be placed in 4% PFA followed by 80% ethanol. They will then be paraffin embedded and used in 
IHC and ISH studies.  The remaining samples will be immediately placed into RPMI and transferred to the Schacker lab for preparation of cell suspensions. Distribution of isolated cells is detailed in the Specimen Management Plan in the study files.  
 
8. STUDY	SCHEDULE 						
8.1 Schedule 	for	HIV	infected	subjects 	(n=50)	
 Screening  
At this visit, consents will be reviewed in detail and the subject will have the opportunity to ask any questions they may have.  Subjects will be asked if they would like to participate in the additional two-
Reversing Tissue Fibrosis to Improve  Immune Reconstitution in HIV 
 
Protocol Version 6.6  
March 1, 2017 	 Page 27	
 photon microscopy sub-study which entails additional blood draws at several scheduled study visits.  
Designated study staff or physician will interview the participant and a physical exam (which includes 
vital signs and exam of heart, lungs, abdomen, neurologic  and lymphatic systems) will be performed.  
Blood will be obtained for CD4 T cell count, HIV VL, HIV antibody, liver function tests, electrolyte panel 
including creatinine, and complete hematology count (CBC - white blood cell count with differential, 
hemoglobin and platelets).  Screening for hepatitis C will also be performed.  Women of childbearing age will have a urine pregnancy test. Once lab results are available (within 3 days), they will reviewed by 
[CONTACT_530304]/exclusion criteria are met. If the subject has met all entry criteria, they will be contact[CONTACT_530305].  The study protocol will again 
be reviewed and if they are still interested in enr olling, they will be scheduled for the day [ADDRESS_688683] not met the criteria will also be contact[CONTACT_530306].  At this visit, an “enroll by [CONTACT_568]” will be designated that is no 
more than 60 days from the screen date to ensure screening labs are no more than 60 days old at the time of randomization. If more than 60 days passes between “Screen” and randomization, a comprehensive chemistry panel will be redrawn with the results known to be within study-required 
parameters prior to randomization.  
 
 Baseline Visit  
Designated study staff will review medical history wi th the participant and perform a targeted physical 
exam (vitals, heart, lung, abdomen, neurologic system). The subject will not be randomized until lab results have been reviewed and found to be within limits designated in the protocol. The designated study staff or principal investigator [INVESTIGATOR_530242] [ADDRESS_688684] still meets all eligibility 
criteria. Blood will then be drawn for CBC, compr ehensive metabolic panel (CMP – includes electrolytes, 
creatinine, and liver function tests), CD4 and VL as well as plasma, serum and PBMCs for study 
endpoints.  Subjects in the two-photon microscopy sub-study will also have an additional 90cc of blood drawn.  Inguinal LN biopsy and colonoscopy with ileal and rectal biopsies will be performed (described in 
detail in section 7.1 above). They will remain in the MCRU for [ADDRESS_688685] by [CONTACT_530307] 7 to check for tolerability. 
  
 Day 14 Visit 
Subjects will be seen at day 14 for clinical assessment  (interval history and targeted exam), assessment 
of drug adherence and to obtain toxicity labs (CBC and CMP).  If the subject meets the following criteria: 
lack of dizziness, lightheadedness, or faintness upon rising, confusion, palpi[INVESTIGATOR_814], and cough; GFR greater than or equal to 30 ml/min/1.73 m2 and potassium level less than or equal to 5.0, the dose of losartan/placebo will be increased to 100 mg po daily.  The maximal tolerable dosage (up to 100 mg a day) will be continued for a total of 30 months.   
 
At Day 14, side effects and blood chemistries (comprehensive chemistry panel) will be assessed. The dose of losartan/placebo will increase to 100mg daily at this Day 14 visit (i.e., once lab results return) if all of the following criteria are met:  
a) Systolic blood pressure (BP) ≥90 mmHg  
b) Potassium ≤5.0 mmol/L  
c) eGFR ≥30 mL/min/1.73m
2 
Reversing Tissue Fibrosis to Improve  Immune Reconstitution in HIV 
 
Protocol Version 6.6  
March 1, 2017 	 Page 28	
 d) Lack of a grade ≥ [ADDRESS_688686] evaluation deemed possibly/probably related to 
the study drug.  
e) Lack of significant side effects deemed related to study drug (e.g., lightheaded upon 
standing)  
f) Lack of other concerns to increase study drug dosing, as determined by [CONTACT_530308]/or have side effects assessed at any point during the 
study, per the discretion of the site investigator.  If participants are increased to 100mg daily (or 
matching placebo) they will maintain this dose for the duration of the 30-month study unless new side 
effects or adverse events necessitate re-evaluation (see below criteria for dose reduction or stoppi[INVESTIGATOR_14930]).  
If participants do not increase dose to 100mg daily at the week 2 visit (e.g., if symptomatic or if systolic 
BP is not ≥90 mmHg), the criteria for dose escalation may be reassessed at the 1-month visit. If 
participants do not meet criteria for dose increase (from 50mg to 100mg daily) after the 1-month visit, they will be maintained on 50mg dose until the month [ADDRESS_688687] five criteria above are met (a-e).  At any point when participants have dose 
increased from 50mg to 100mg, they will be contact[CONTACT_30781] [ADDRESS_688688] clinical labs drawn to assess toxicity; a full study visit for side effect and adverse event 
documentation can occur at any point, per the discretion of the site investigator.   Dose Reduction: Tolerability, side effects, and clinical laboratory monitoring will be assessed at each study visit (via participant report and clinical labs), and at any other time point at the discretion of the 
clinical site investigator.  Adverse events that are assessed as related to study drug will prompt re-
evaluation via phone or as an adverse event visit, per clinical discretion of the site investigator. If this event worsens or does not resolve after re-e valuation, then study medication dose should be decreased 
(i.e., from 100mg to 50mg) or stopped (if taking 50mg daily).  If signs and symptoms resolve after 2 weeks, then the participant may resume or increase dose (i.e., back to 100mg if previously reduced to 
50mg daily), per the clinical discretion of the site investigator. 
 Stoppi[INVESTIGATOR_56985]:  If an adverse event of grade ≥3 is assessed as related to study drug, study 
medication should be stopped and the participant should be re-evaluated in 2 weeks.  If a grade 2 rash is persistent, study medication may also be stopped at the discretion of the site investigator and the participant should be re-evaluated in 2 weeks. If signs and symptoms resolve after 2 weeks, then the 
participant may be re-challenged at a lower dose (i.e., at 50mg if previously taking 100mg daily) per the clinical discretion of the site investigator.  If study medication is stopped for an adverse event that is later 
determined NOT to be related to study medication, then the medication may be resumed at 50mg and increased to 100mg per initial criteria for dose escalation and at the discretion of the clinical site investigator.  
 
 Month 1 Visit 
Subjects will be seen at month 1 for clinical assessm ent (interval history and targeted exam) and review 
of drug adherence.  Blood will be drawn.  They w ill then take their daily ART and study drug and will 
remain in the MCRU for additional blood draws at 1, 2, 3, 4, 6, 8, and 12 hours after drug administration 
in order to intensively study the pharmacokinetics of ARTs and losartan.  They will then return to the MCRU the following morning for one additional blood draw at 24 hours after drug administration.  
 
 Months 3, 6, 9, 15, 18, 21 and 27 Visits  
Subjects will be seen for clinical assessment (inter val history and targeted exam), review of drug 
adherence, refill of study drug, and blood draw for CBC, CMP, CD4, VL, plasma, serum and PBMCs. 
 
Reversing Tissue Fibrosis to Improve  Immune Reconstitution in HIV 
 
Protocol Version 6.6  
March 1, 2017 	 Page 29	
 
 Month 12 Visit 
Subjects will be seen at month 12 for clinical assessment  (interval history and targeted exam), review of 
drug adherence, refill of study drug, and blood draw for CBC, CMP, CD4, VL, plasma, serum and 
PBMCs.  Subjects in the two-photon microscopy sub-study will also have an additional 90cc of blood 
drawn .  Subjects will then undergo repeat inguinal LN biopsy and colonoscopy with rectal and ileal 
biopsies.  They will remain in the MCRU for 4 h ours after procedures for clinical monitoring. 
 
 Month 23 Visit 
Subjects will be seen for clinical assessment (inter val history and targeted exam), review of drug 
adherence, refill of study drug, and blood draw for CBC, CMP, CD4, VL, plasma, serum and PBMCs.  In addition, the first dose of Gardasil (human papi[INVESTIGATOR_530243]) will be administered.  Subjects will remain in the MCRU for 30 minutes after administration for monitoring.  
 Month 25 visit 
Subjects will return for clinical assessment (int erval history and targeted exam), review of drug 
adherence, refill of study drug and blood draw for plasma, serum and PBMCs.  The second dose of Gardasil will then be administered. Subjects will remain in the MCRU for 30 minutes after administration 
for monitoring.  
 Month 29.5 Visit 
Subjects will be seen for clinical assessment (inter val history and targeted exam), review of drug 
adherence and blood draw for CBC, CMP, CD4, VL, plasma, serum and PBMCs.  In addition, the third and final dose of Gardasil will be administered. Subjects will remain in the MCRU for 30 minutes after administration for monitoring.  
 Month 30 Visit (Final Study Visit) 
Subjects will be seen at the end of month 30 for the final scheduled study visit. Clinical assessment (interval history and targeted exam) and review of drug adherence will be performed and any remaining 
study drug will be collected by [CONTACT_519697].  Blood will be drawn for CMP, CBC, HIV VL, CD4 T cell count, serum, plasma, and PBMCs.  Subjects in the two-photon microscopy sub-study will also have an additional 90cc of blood drawn. Subjects will undergo final biopsy procedures (ileal, rectal, 
and lymph node). They will remain in the MCRU for 4 hour s after procedures for clinical monitoring. 
They will complete the off-study form prior to discharge from the MRCU.  Subjects will be instructed to report any subsequent event(s) within [ADDRESS_688689]’s 
personal physician, believes might reasonably be related to participation in this study.
   
 
 Early Termination Visit 
Participants may withdraw voluntarily from the study at any time.  If a subject opts to discontinue, 
attempts will be made to schedule and conduct an early termination visit for medical assessment and return of any unused study drug for proper disposal.  If a subject withdraws after an adverse event (AE), they will be followed until resolution of the issue or until their condition is stable.   
 
 Pregnancy Visit 
In the event that a study subject becomes pregnant, termination, reporting, and follow-up procedures 
outlined in Section 9.[ADDRESS_688690] 
concerns, etc.  
Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV 
 
Protocol Version 6.6  
March 1, 2017 	 Page 30	
  
8.2 Schedule 	of	Events	for	HIV	Infected 	Subjects 	
 
 
Table 1. Protocol summary for HIV infected subjects: 
 
  Screen Day 
0 Day 
14 Month 
1 Months  
3, 6, 9, 
15, 18, 
21, 27  Month 
12 Month 
23 Month 
25 Month 
29.5 Month 
30 
Medical history X X                
Interval medical history   X X X X X X X X 
Physical Exam1 X X X X X X X X X X 
Adherence assessment and 
counseling  X X X X X X X X X 
Pregnancy test2 X X    X  X   X  X  X   
HCV Ab X                 
CMP X X  X X X X X   X X 
CBC w diff X X X X X X X   X X 
CD4 count X X   X X X X   X X 
HIV viral load X X    X X X X   X X 
Serum3   X   X X X X X  X X 
Plasma /PBMCs4   X   X X X X X  X X 
Additional PBMCs5  X    X    X 
Biopsies6   X       X     X 
HPV vaccine7             X X X   
PK assessment       X8 X9 X9  X9   X10 
 
1. At screening, a full physical exam will be performed (described above).  At subsequent visits, a targeted 
exam will be performed.  
2. Women of childbearing age must have a negative pregnancy test prior to enrollment.  Pregnancy testing 
will also occur roughly every [ADDRESS_688691] biopsy and colonoscopy with sampling of ileal and rectal tissues. 7. Human papi[INVESTIGATOR_530244] (Gardasil) will be administered at [ADDRESS_688692] and 
GALT will be determined at month 30. 
 
Reversing Tissue Fibrosis to Improve  Immune Reconstitution in HIV 
 
Protocol Version 6.6  
March 1, 2017 	 Page 31	
 8.3 Schedule 	for	Control	‐	HIV	Uninfected 	Subjects 	(n=5)	
 Screening  
At this visit, consents will be reviewed in detail and the subject will have the opportunity to ask any 
questions they may have. The designated study staff or  physician will interview the participant and a 
physical exam will be performed.  Blood will be obtained for HIV antibody, liver function tests, electrolyte 
panel including creatinine, and CBC.  Screening for hepatitis C will also be performed.  Women of childbearing age will have a urine pregnancy test. Once lab results are available (within 3 days), they will reviewed by [CONTACT_530304]/exclusion criteria are met. If the 
subject has met all entry criteria, they will be cont acted by [CONTACT_519697].  The study 
protocol will again be reviewed and if the subject is still interested in enrolling, they will be scheduled for the study visit.  Subjects who have not met the criteria will also be contact[CONTACT_530309].  
 Study Visit 
Designated study staff will review medical history wi th the participant and perform a targeted physical 
exam.  Blood will then be drawn for CD4, plasma, serum and PBMCs.  Inguinal LN biopsy will be 
performed. The subject will remain in the MCRU for 4 hours after procedures for monitoring. They will 
complete the off-study form prior to discharge from the MRCU. Subjects will be instructed to report any subsequent event(s) within [ADDRESS_688693]’s personal physician, believes might reasonably be r elated to participation in this study.
   
 
8.4 Schedule 	for	Additional 	5	Control	HIV	Uninfected 	Subjects 	(n=5)	
Our first experiments with human tissue demonstrated that we need to change procedures for handling and imaging the tissue.  The first few controls were not fully interpretable because of this.  In addition the data we are generating suggests that increasing the number of controls by [ADDRESS_688694]. Once lab results are available (within 3 days), they will reviewed by [CONTACT_530304]/exclusion criteria are met. If the 
subject has met all entry criteria, they will be cont acted by [CONTACT_519697].  The study 
protocol will again be reviewed and if the subject is still interested in enrolling, they will be scheduled for the study visit.  Subjects who have not met the criteria will also be contact[CONTACT_530310]-Study 
Within two weeks of the biopsy a MRI will be scheduled, see Appendix I for MRI sub-study protocol. 
 
 Study Visit(s) 
If subject agrees to participate in the trial they will return to the MCRU to receive Stribild and Prezista.  
The subjects will take these medications for two weeks and return to be seen by [CONTACT_524255].  At this time a review of the medical history with the participant and a targeted physical exam will 
be performed.  Blood will then be drawn for CD4, plasma, serum and PBMCs.  Inguinal LN biopsy with colonoscopy with ileal and rectal biopsies will be performed.  During this time blood draws will be taken at baseline and hours 1,2,3,4,6,8,12, and [ADDRESS_688695] will remain at the 
Reversing Tissue Fibrosis to Improve  Immune Reconstitution in HIV 
 
Protocol Version 6.6  
March 1, 2017 	 Page 32	
 MCRU for 12 hours for monitoring.  They will then return to the MCRU the following morning for one 
additional blood draw at 24 hours after drug administration. T hey will complete the off-study form prior to 
discharge from the MRCU. Subjects will be instructed to report any subsequent event(s) within [ADDRESS_688696]’s personal physician, believes might reasonably be 
related to participation in this study.   
8.5 Schedule 	of	Events	for	Additional 	5	Control	HIV	Uninfected 	Subjects 	
 
Table 2. Protocol summary for HIV uninfected (control) subjects: 
 
 Screen Study Drug 
 Pi[INVESTIGATOR_9696]-Up MRI Week 2 
Medical history  X    
Interval medical history     X 
Physical Exam1 X   X 
Safety screening   X  
MRI   X  
Adherence counseling   X   
Pregnancy test2 X    
HIV & HCV Ab  X    
CMP  X   X 
CBC w diff  X   X 
CD4 count X   X 
Serum3    X 
Plasma /PBMCs4    X 
Biopsies5    X 
PK assessment6    X 
 
1. At screening, a full physical exam will be performed.  At the Week [ADDRESS_688697] biopsy and colonoscopy with sampling of ileal and rectal tissues. 6. Intensive 24-hour PK assessment  
 
9. ASSESSMENT 	OF	SAFETY	
9.1 Definition 	of	an	Adverse 	Event	(AE)	
 Basic Definition 
An AE is any symptom, sign, illness, or experienc e that develops or worsens in severity during the 
course of the study but does not necessarily have a causal relationship with a study agent/intervention or procedure.  An AE can therefore be any unfavorable and unintended sign (including an abnormal 
laboratory finding), symptom, or disease temporally  associated with the use of the study 
agent/intervention or procedures whether or not it is re lated to the study agent/intervention.  Intercurrent 
Reversing Tissue Fibrosis to Improve  Immune Reconstitution in HIV 
 
Protocol Version 6.6  
March 1, 2017 	 Page 33	
 illnesses or injuries will be regarded as AEs.  Abnor mal results of diagnostic procedures are considered 
to be AEs if the abnormality: 
 results in study withdrawal, 
 is associated with a serious adverse event (SAE), 
 is associated with clinical signs or symptoms, 
 leads to additional treatment or to further diagnostic tests, or  is considered by [CONTACT_125943]. 
 
 Definition of a Serious Adverse Event (SAE) 
Adverse events are classified as serious or non-serious.  An SAE is any AE that is:  
 Fatal,  life-threatening,  requires or prolongs a hospi[INVESTIGATOR_4408],  results in persistent or significant disability or incapacity, 
 a congenital anomaly or birth defect, or 
 an important medical event. 
Important medical events are those that may not be i mmediately life threatening, but are clearly of major 
clinical significance.  They may jeopardize the subject, and may require intervention to prevent one of 
the other serious outcomes noted above.  For example, drug overdose or abuse, a seizure that did not result in inpatient hospi[INVESTIGATOR_059], or intensive treatment of bronchospasm in an emergency department 
would typi[INVESTIGATOR_15355]. All AEs that do not  meet any of the criteria for serious should be 
regarded as non-serious AEs.  
 Definition of a Suspected Unexpected  Serious Adverse Reaction (S[LOCATION_003]R) 
An AE that is: • Serious (i.e., an SAE), • Related (i.e., there is a reasonable possibility that the AE may be related to the study product), and • Unexpected (i.e., an AE whose nature or severity [intensity] is not consistent with the applicable  
product information found in an investigator’s brochure, a package insert or a summary of agent 
characteristics).   
 Preexisting Condition 
A preexisting condition is one that is present at t he start of the study.  A preexisting condition will be 
recorded as an AE if the frequency, intensity, or character of the condition worsens during the study period. 
 
 Post-study Adverse Event 
All unresolved AEs will be followed by [CONTACT_530311], the subject is lost to 
follow-up, or the AE is otherwise explained.  At the last scheduled visit, the Investigator will instruct each 
subject to report any subsequent event(s) within [ADDRESS_688698]’s personal physician, believes might reasonably be related to participation in this study.   
 
 Abnormal Laboratory Values 
A clinical laboratory abnormality should be documented as an AE if any 1 of the following conditions is met:  
 The laboratory abnormality is not otherwise refuted by a repeat test to confirm the 
abnormality, 
Reversing Tissue Fibrosis to Improve  Immune Reconstitution in HIV 
 
Protocol Version 6.6  
March 1, 2017 	 Page 34	
  The abnormality suggests a disease and/or organ toxicity, or 
 The abnormality is of a degree that requires active management; e.g., change of dose, 
discontinuation of the drug, more frequent follow-up assessments, further diagnostic 
investigation, etc. 
 
 Hospi[INVESTIGATOR_059], Prolonged Hospi[INVESTIGATOR_059], or Surgery 
Any AE that results in hospi[INVESTIGATOR_43355] a 
SAE unless specifically instructed otherwise in this protocol.  Any condition responsible for surgery 
should be documented as an AE if the condition meets the criteria for an AE.  Neither the condition, nor hospi[INVESTIGATOR_059], nor prolonged hospi[INVESTIGATOR_059], nor surgery are reported as an AE in the following circumstances: 
 Hospi[INVESTIGATOR_14841] 
a preexisting condition.  Surgery should not be reported as an outcome of an AE if the 
purpose of the surgery was elective or diagnostic and the outcome was uneventful. 
 Hospi[INVESTIGATOR_201728]. 
 Hospi[INVESTIGATOR_14843], 
unless it is a worsening or increase in frequency of hospi[INVESTIGATOR_530245]. 
 
 Anticipated Adverse Events  
AEs are not anticipated, but there are AEs associated with the use of both study agents and with the 
procedures being performed in the study. Possible AEs are described above in section 7.[ADDRESS_688699] ribild, Prezista, or Gardasil use or from any of 
the study procedures.  
 
9.2 Unanticipated 	Problems 	
Unanticipated problems (UP), as defined by [CONTACT_68407], experience, or outcome that 
meets all of the following criteria: 
1. Unexpected (in terms of nature, severity, or fr equency) given (a) the research procedures that are 
described in the protocol-related documents, such as  the IRB-approved research protocol and informed 
consent document; and (b) the characteristics of the subject population being studied; 
2. Related or possibly related to participation in the research (in this guidance document, “possibly related” 
means there is a reasonable possibility that the incident, experience, or outcome may have been caused 
by [CONTACT_3459]); and 
3. Suggests that the research places subjects or others at a greater risk of harm (including physical, 
psychological, economic, or social harm) t han was previously known or recognized. 
Upon becoming aware of any AE, the PI [INVESTIGATOR_530246].  If the PI [INVESTIGATOR_530247], 
the PI [INVESTIGATOR_530248].  In 
addition, incidents, experiences and outcomes that occur dur ing the conduct of this study that represent 
unanticipated problems but are not considered AEs may require reporting under the HHS regulations at 45 
Reversing Tissue Fibrosis to Improve  Immune Reconstitution in HIV 
 
Protocol Version 6.6  
March 1, 2017 	 Page 35	
 CFR 46.103(a) and 46.103(b)(5).  Further details and examples of such scenarios are described in the 
OHRP policy ( http://www.hhs.gov/ohrp/policy/advevntguid.html#Q1 ).  Unanticipated problems involving risks 
to participants or others will be reported as detailed in the DAIDS Critical Event Policy (http://www.niaid.nih.gov/LabsAndResources/res ources/DAIDSClinRsrch/Pages/Safety.aspx ).   
 
9.[ADDRESS_688700] seek information as to discomforts or adverse experiences by [CONTACT_5147], as appropriate, by  [CONTACT_5148]. At study visits, safety laboratory 
evaluations will also be performed to identify any laboratory AEs.  All side effects will be reported to the PI 
[INVESTIGATOR_1238]/or physician co-investigators on a daily basis and toxi city laboratory results will be reviewed in real time .
  
Information about AEs to be recorded includes event description, time of onset, investigator assessment of 
severity, relationship to study agent(s)/Intervention(s), and time of resolution/stabilization of the event.  All AEs occurring during the study period (from time of consent signing to [ADDRESS_688701] study visit)  
must be documented appropriately regardless of relationship  to study products or procedures.  Information 
on all AEs will be promptly recorded in the source document and also in the appropriate AE module of the case report form (CRF).    Any medical condition that is present at the time that the participant is screened should be considered as baseline and not recorded as an AE.  However, if the condition deteriorates at any time during the study it 
should be recorded and reported as an AE.  Changes in the severity of an AE should be documented to 
allow an assessment of the duration of the event at eac h level of intensity to be performed.  Adverse events 
characterized as intermittent require documentation of the onset and duration of each epi[INVESTIGATOR_1865].  Changes in the assessment of relationship to the study agent(s)/ interventions should also be clearly documented. 
 
 Scales Used to Grade Seve rity of Adverse Events 
The grading system for severity of AEs is located in the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 1.0, December 2004 (Clarification August 2009), which can be found on the DAIDS RSC Web Site:  http://rsc.tech-res.com/safetyandpharmacovigilance/. 
 
 Scales Used to Attribute Adverse Events 
The Principal Investigator [INVESTIGATOR_530249]: 1. Definitely Related: There is clear evidence to  suggest a causal relationship, and other possible 
contributing factors can be ruled out. The clinical event, including an abnormal laboratory test result, occurs in a plausible time relationship to study agent/intervention administration and cannot be explained by [CONTACT_9153]. The response to withdrawal of the study 
agent/intervention (de-challenge) should be clinically plausible. The event must be pharmacologically 
or phenomenologically definitive, with use of a sa tisfactory re-challenge procedure if necessary. 
2. Probably Related: There is evidence to suggest a causal relationship, and the influence of other factors 
is unlikely. The clinical event, including an abnormal laboratory test result, occurs within a reasonable time sequence to administration of the study agent/ intervention, is unlikely to be attributed to 
concurrent disease or other drugs or chemic als, and follows a clinically reasonable response on 
withdrawal (de-challenge). Re-challenge information is not required to fulfill this definition.  
3. Possibly Related: There is some evidence to suggest a causal relationship (e.g., the event occurred 
within a reasonable time after administration of the trial medication). However, the influence of other factors may have contributed to the event (e.g., the subject’s clinical condition or other concomitant 
events). Although an adverse drug event may rate only as “possible” soon after discovery, it can be 
flagged as requiring more information and later be upgraded to “probable” or “certain” as appropriate. 
4. Unlikely: A clinical event, including an abnormal laboratory test result, whose temporal relationship to 
study agent/intervention administration makes a causal relationship improbable (e.g., the event did 
Reversing Tissue Fibrosis to Improve  Immune Reconstitution in HIV 
 
Protocol Version 6.6  
March 1, 2017 	 Page 36	
 not occur within a reasonable time after administration of the trial medication) and in which other drugs 
or chemicals or underlying disease provides plausible explanations (e.g., the subject’s clinical 
condition or other concomitant treatments). 
5. Not Related: The AE is completely independent of study agent/intervention administration, and/or 
evidence exists that the event is definitely relat ed to another etiology. There must be an alternative 
and definitive etiology documented by [CONTACT_15370].  
 
 Analysis/Management 
The clinical course of each event will be followed until resolution, stabilization, or until it has been determined that the study treatment or participation is not the cause.  Any measures taken or follow-up results are to be recorded in the study file.  In addition, any clinically meaningful incidental findings from 
colonoscopi[INVESTIGATOR_530250]’s primary care 
provider by [CONTACT_6791], e-mail, letter, and/or telephone call.  Documentation of appropriate follow up and reporting 
of all AEs will consist of written telephone contact [CONTACT_120942], faxes, e-mail messages, and/or letters, which will be kept in the study files.  SAEs that are still ongoing at the end of the study period must be followed to determine the final outcome. Study physicians will be re sponsible for evaluating subjects in the case of AEs.  
Study physicians and study staff are responsible for communicating to subjects information arising from the 
study (on harm or benefit, for example), or from other research on the same topic that could affect subjects’ 
willingness to continue in the study.   
 
9.4 Reporting 	Procedures 	
 AEs to be Reported 
The following AEs will be promptly reported within three reporting days to the DSMB and the DAIDS 
medical monitor:  
   
 all cancers, all autoimmune diseases, all fetal losses associated with an AE,  
 all overdoses associated with an AE, and   any definitely related, unexpected, and serious adverse events (S[LOCATION_003]RS).  
 
Other AEs or unanticipated problems will be reported to the IRB and DSMB within their reporting timelines (such as annual review or if prompt reporting is required, within the urgent reporting timeline requirements).  
 
At the time of the initial report, the following information should be provided: 
 Study identifier, 
 Subject number,  A description of the event, 
 Date of onset, 
 Current status,  Whether study treatment was discontinued,  The reason why the event is classified as serious, and  Investigator assessment of the assoc iation between the event and study treatment. 
 
Copi[INVESTIGATOR_530251]’s binder. All reportable AEs will be followed until satisfactory resolution or until the PI [INVESTIGATOR_54720]-investigator deems the event to be chr onic or the participant to be stable. If a previous SAE 
that was not initially deemed reportable under expedited repo rting criteria is later found to fit the criteria 
Reversing Tissue Fibrosis to Improve  Immune Reconstitution in HIV 
 
Protocol Version 6.[ADDRESS_688702] of adverse 
events and complications will be reviewed by [CONTACT_530312] .  
 
Table: Expedited Reporting to IRB, DSMB and DAIDS 
 
Expedited Reporting 
to Whom 
 Criteria for 
Reporting Timeframe Submission Format  
IRB  Unanticipated death 
of a locally enrolled 
subject(s);  New or increased risk; 
Any adverse event 
that requires a change to the protocol or 
consent form; 
Unanticipated problems; 
Refer to the IRB 
website for complete details on required 
reporting criteria. 5 working days Local IRB’s standard 
reporting form 
DSMB  1) S[LOCATION_003]RS 
2) all cancers, all 
autoimmune 
diseases, all fetal 
losses associated with an AE, and all 
overdoses associated 
with an AE 
3) Unanticipated 
death of locally enrolled subject(s) 3 reporting days (defined as M-F, including holidays) Submit AE/SAE CRF, and IRB Report form, if available. 
DAIDS  
 1) S[LOCATION_003]RS 
2) all cancers, all 
autoimmune diseases, all fetal 
losses associated with 
an AE, and all overdoses associated 
with an AE 
3) Grade 3 and 4 AEs that are attributed to 
study procedures 
(graded as per section 9.3.1 above) 3 reporting days 
(defined as M-F, 
including holidays) Submit SAE/AE CRF to 
DAIDS medical officer. 
 
 Expedited Adverse Event (E AE) Reporting to DAIDS 
EAE	Reporting 	to	DAIDS	
The definitions of AEs requiring expedited reporting are outlined in Version 2.0 of the DAIDS EAE 
Manual, which is available on the DAIDS RSC website at  http://rsc.tech-
res.com/safetyandpharmacovigilance/ .   
 
Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV 
 
Protocol Version 6.6  
March 1, 2017 	 Page 38	
 	 						 EAE	Reporting 	Requirements 	for	the	Study	
The events for which expedited reporting is r equired include Suspected, Unexpected Serious 
Adverse reactions (S[LOCATION_003]Rs). In addition to the EAE Reporting Category identified above, other AEs 
that will be reported in an expedited manner include all cancers, all autoimmune diseases, all fetal losses associated with an AE, all overdoses associated with an AE and all Grade 3 and 4 AEs that are attributed to study procedures (graded as per section 9.3.1 above).   
The timeline for reporting of expedited events to the DAIDS medical officer is as defined in the DAIDS 
EAE manual.  
 The study agents for which expedited reporting is required are losartan, placebo for losartan, Gardasil, darunavir, and elvitegravir/cobicistat/emtricitabine/tenofovir.  
Grading	Severity	of	EAEs	
The grading table used for this study is the DAIDS Table for Grading the Severity of Adult and 
Pediatric Adverse Events, Version 1.0, December 2004 (Clarification August 2009), which can be 
found on the DAIDS RSC Web Site:  http://rsc.tech-res.com/safetyandpharmacovigilance/ . 
 
Expedited 	AE	Reporting 	Period	
The reporting period will be from the time the subject starts the study drug until the end of the study follow up for that participant. After the protocol-defined AE reporting period, only S[LOCATION_003]Rs as defined in Version 2.0 of the EAE Manual will be reported to the IRB and DSMB if the study staff become 
aware of the events on a passive basis (from publicly available information). A copy of these reports 
will also be sent to the DAIDS Medical Officer. 
9.5 Reporting 	a	Pregnancy 	
Pregnant women are not eligible to participate in the study. Women are counseled regarding prevention of pregnancy and encouraged to make every effort to avoid pregnancy during study participation.  In addition to the screening and baseline visits, pregnancy testing will occur every 3 months and anytime during follow 
up when the woman or investigator suspects pregnancy.  If a study participant becomes pregnant during 
study participation, no further doses of losartan or Gardasil will be given and no additional study procedures 
will be performed.  Basic information about the pregnancy will be recorded on the “Pregnancy” CRF and permission to record survival data for her until the end of the pregnancy and of the baby [CONTACT_530313].  If there are complications during the pregnancy, the complications are recorded as AEs in the 
usual way. The participant is asked to report outcome of the pregnancy. If there is a congenital anomaly in 
the infant, this is recorded as a serious adverse event  (SAE) in the data forms for the mother (i.e., the study 
participant).   
 
9.6 Toxicity	Management 	
The grading system for drug toxicities is located in  the DAIDS Table for Grading the Severity of Adult and 
Pediatric Adverse Events, Version 1.0, December 2004 (Clarification August 2009), which can be found on the DAIDS RSC Web Site:  http://rsc.tech-res.com/safetyandpharmacovigilance/. Participants experiencing side effects related to losartan, will be evaluated immediately by a study physician and may be referred to their primary HIV provider for evaluation and treatment if indicated.  Subjects who develop drug-related toxicity of Grade 1 or 2 may continue study participation.  If a participant experiences any drug-related 
toxicity >Grade 2 and it is judged to be due to losartan, losartan will be discontinued.  If a participant 
experiences any drug-related toxicity >Grade [ADDRESS_688703] and 
prior to the enrollment of any subjects, the DSMB will develop the DSMB charter, which includes triggers 
set for stoppi[INVESTIGATOR_530252].  Subsequent review of serious, 
unexpected and related adverse events by [CONTACT_1689], DSMB, ethics review committee or IRB, 
the sponsor(s), and other regulatory authorities may also result in suspension of further trial interventions/administration of study agent at a site.  The study sponsor(s) and other regulatory agencies retain the authority to suspend addition al enrollment and study agent(s)/intervention(s) 
administration for the entire study as applicable. 
 
 Stoppi[INVESTIGATOR_530253] (and all follow-up procedures) for any reason and at any time. 
Participants may also choose to discontinue study medication and continue all follow-up procedures.  This is most likely in the event of a toxicity that, in the opi[INVESTIGATOR_7372], is related to the study agents.    
If a subject withdraws, attempts will be made to schedule and conduct an early termination visit as 
described in section 8.1.11.  The reason and date of withdrawal will be documented on the subject’s CRF.  Date of withdrawal will be documented as the date of last study drug treatment, not the date that the decision to withdraw was made.  Participants w ill be followed after withdrawal from the study for [ADDRESS_688704] their safety or if participants are unable or unwilling to 
comply with visits, study procedures, or study medicat ion.  Participants will be removed from the study if 
they experience any drug-associated toxicity > grade 2 and it is judged to be due to losartan (e.g., a complication of the biopsy procedure may not necessitate removal from the study).  Subjects will not be withdrawn if they experience toxicity > grade 2 that  is deemed due to Gardasil but will not continue to be 
given Gardasil.  Subjects will also be removed in the event of pregnancy. Healthy controls will be 
removed from the study if they experience rash, moderate GI symptoms and/or symptoms consistent with clinical hepatitis with no other medically reasonable cause. Other exit criteria include: 
 completion of the study,  
 withdrawal of consent,   moving to an area that would prohibit the subject from returning for visits, and   death. 
 
Even though subjects may be withdrawn prematurely from  the study, we will continue to collect survival 
data on such subjects throughout duration of the [ADDRESS_688705] withdrawn from the study prior to Month 1 will be replaced by [CONTACT_530314].  
 
Reversing Tissue Fibrosis to Improve  Immune Reconstitution in HIV 
 
Protocol Version 6.6  
March 1, 2017 	 Page 40	
 9.8 Unblinding 	Procedures 	
The Investigational Drug Service (IDS) Pharmacy is responsible for the administration of the blinded study 
agent as the intervention. This pharmacy holds the reco rd of randomization for this study. The study 
participant, investigators, study coordinator, other study staff, statistician, and DSMB are blinded. The following conditions or events in which unblinding may occur are: 
 
 Emergency Unblinding  
Please see Fairview IDS Pharmacy Emergency Blind SOP for detailed description of the unblinding process that will occur in the case of an emergency.  
 
 Individual Unblinding 
For individual unblinding, the PI [INVESTIGATOR_530254] a SAE has occurred and 
the treatment or allocation code is required in order to enable clinical treatments to be planned. In the event that this occurs, the IDS pharmacy will be cont acted by a member of the study staff and given the 
following details: caller name [CONTACT_530336], study site, site investigator, name [CONTACT_7481], study protocol number, and subject identification number. Upon unblinding, the study staff member will record 
the participant withdrawal and allocation in the person’s clinical and trial notes along with appropriate 
clinical notations. The study staff member will log the unblinded reports and the PI [INVESTIGATOR_530255], DSMB, OHRP, and DAIDS. 
 
 Unmasked Analysis 
The DSMB will determine that an unmasked analysis is required. The decision will be documented in the committee meeting minutes.  A DSBM designee will make a written request to the PI [INVESTIGATOR_530256]. The PI [INVESTIGATOR_530257]. The IDS pharmacy will check the allocation log for completions to date, sign and date the last 
entry with a note to indicate point of request, and provide the DSMB designee with the register of all 
study allocations. The lead statistician will merge the study data with the table of allocation codes as per the data transfer instructions within the dat a management plan and undertake unmasked analysis as 
determined by [CONTACT_4318]. 
 
 Unblinding Upon Study Completion 
The PI [INVESTIGATOR_530258]. A study staff member will contact [CONTACT_530315] a request for return all unblinded 
study agent. The IDS pharmacy will check the allocation log for completion, sign and dater the last entry, provide the study staff member with the schedule of all study allocations, and ensure all invoicing has 
been completed. The study staff member will enter all identification numbers and allocations into a file and send the file to the statistician as outlined in the Data Management Plan. The statistician will confirm 
receipt of the file containing the ID numbers and allocat ions, and merge the study data with the new file 
in preparation for analysis.  
 
10. CLINICAL 	MONITORING 	STRUCTURE	
10.[ADDRESS_688706] (DSMB) 
A DSMB will be assembled by [CONTACT_137025]’s Clinical and Translational Science Institute 
(CTSI). This DSMB will have at least [ADDRESS_688707] one member with relevant clinical expertise and/or experience.   
 It is the role of the DSMB to protect trial subjects and to provide impartial advice and assistance to the PI 
[INVESTIGATOR_530259], so as to protect the validity and credibility of the trial.  The DSMB will have access to the clinical prot ocol, interim data, adverse event reports, clinical 
monitoring reports, annual and/or progress reports submitted to the IRB and/or regulatory agency, and correspondence between the PI [INVESTIGATOR_530260].   The relationship between the DSMB and the PI [INVESTIGATOR_530261]. The specific roles of this DSMB will be to: 
 Assess data quality, including completeness.  
 Monitor compliance with the protocol by [CONTACT_530316].  Monitor recruitment progress and losses to follow up.    Monitor evidence for treatment differences  in the main efficacy outcome measures. 
 Monitor evidence for treatment harm (SAEs). 
 Advise on protocol modifications suggested by [CONTACT_530317]. 
 Develop and/or monitor clinical trial stoppi[INVESTIGATOR_004].  Recommend and/or decide whether trial termination is appropriate. 
 
DSMB members shall disclose potential competing int erests, both financial and intellectual.  Members 
shall not use interim trial results to inform trading in pharmaceutical or device company shares or stock 
in competing companies.  
 The initial DSMB meeting will occur within the first two m onths of the study period, prior to enrollment of 
subjects.  At this meeting the DSMB will discuss the protocol and the DSMB charter which includes triggers set for data review or analyses, definition of a quorum, and guidelines for monitoring the study. 
Guidelines will also address stoppi[INVESTIGATOR_530262]. At this meeting, the DSMB will also develop procedures for conducting business (e.g., voting rules, attendance, etc.).   The DSMB will then meet at least once annually to examine the accumulated safety and enrollment 
data, review study progress, and discuss other factor s (internal or external to the study) that might 
impact continuation of the study as designed. T he frequency of meetings may be increased if 
unanticipated adverse events (AEs) or safety issues are observed or enrollment rate exceeds 
expectations. A DSMB meeting may be requested by [CONTACT_39129], study sponsor, industrial collaborator, IRB, or study PI [INVESTIGATOR_392532]. Decisions to hold ad hoc meetings 
will be made by [CONTACT_45453]. Meetings may be held by  [CONTACT_220393]-to-face meetings. In the event a DSMB member cannot attend a meeting, he/she may receive a copy of the closed session DSMB report and either participate by [CONTACT_530318].   DSMB meetings will be held in two parts. First, an open section will be held in which demographic data 
and trial progress will be discussed. Quality assurance and compliance issues may be discussed in this 
Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV 
 
Protocol Version 6.6  
March 1, 2017 	 Page 42	
 session, and this session is open to investigators, sponsors, funder, patient advocates, and others as 
appropriate. Open sessions will be followed by [CONTACT_530319]. In closed sessions, the outcomes data will be assessed and recommendations formulated. Closed session meetings may be conducted by [CONTACT_530320].  
 Meeting notes will be prepared from both the open and cl osed sessions within 2 weeks of the meetings. 
The DSMB will not share confidential information, particularly trial interim data with anyone, including the PI. The recommendations of the DSMB will be communicated in writing to the Trial Sponsor, PI, IRB, 
and/or appropriate regulatory agency. The recommendations open to the DSMB will include the 
following: 
• No action required; continue trial as planned. 
• Early termination due to a clear benefit or harm in the interventional group. 
• Early termination due to futility. • Termination of recruitment and/or treatment within a subgroup or single arm of a multi-arm trial. 
• Extending recruitment or follow up for all or individual arms of the protocol. 
 
If immediate action is required, the DSMB Chair will personally notify the DAIDS program officer of any 
findings of a serious and immediate nature or recommendations to discontinue all or part of the trial. In addition to verbal communications, recommendations to  discontinue or substant ially modify the design 
or conduct of a study must be conveyed to DAIDS in writing by e-mail, fax, or courier on the day of the 
DSMB meeting. This written, confidential report may contain unmasked supporting data and include the 
DSMB member's rationale for his/her recommendations.   
11. STATISTICAL 	CONSIDERATIONS 	
11.1 Overview 	and	General	Design	Issues	
From the perspective of statistical analysis, the aims of the proposed study are all quite similar: to determine 
if a randomized intervention has an impact on a longitudi nally observed outcome. Despi[INVESTIGATOR_530263], 
there are differences in the frequency with which some outcomes of interest will be observed and this will impact the details of how the analysis will be conducted. In particular, some variables will be measured 
quarterly (those that are assessed in peripheral blood, such as LPS, IL-6, TNF and ICAM-1) while those 
variables assessed via biopsy (such as the number of Ki67+ cells and the magnitude of the FDC pool) will only be available at baseline, and [ADDRESS_688708] diagnostics will be 
employed to assess the adequacy of the fit and remedial measures (e.g. transforming the outcome variable) 
will be employed as appropriate. The most current version of the statistical software R and the lme package will be used to fit models and examine the data.  Wi th [ADDRESS_688709] 
adequate power to find strong effects; however losartan has not previously been used in the proposed context.   
Analysis of data from the MRI substudy will be descriptive in nature. We are seeking to identify MRI 
methods that will render an image of the inguinal lym ph node that is about to be excised. We will compare 
Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV 
 
Protocol Version 6.[ADDRESS_688710] deviation for collagen deposition of 0.81 (log scale). We can use this estimate to examine the power of a [ADDRESS_688711] to find differences between 2 groups of 25 subjects as this power depends on the magnitude 
of the difference between the 2 groups. 
Difference in average 
of collagen 0.5 0.6 0.7 0.8 
Power 0.59 0.75 0.86 0.94 
 
11.3 Enrollment/Stratification/ Randomization/Blinding 	Procedures 	
HIV infected subjects will be randomized to receive losartan or placebo in a 1:1 manner using ordinary 
methods for generating random deviates. Study staff (other than those in the IDS pharmacy) and participants will be blinded to the random assignments of  all HIV infected study participants. All study drug 
will be supplied in identical containers.  
The two-photon microscopy sub-study of the HIV infect ed subjects requires [ADDRESS_688712] tools (e.g. residual plots).   
 
Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV 
 
Protocol Version 6.6  
March 1, 2017 	 Page 44	
 12. QUALITY 	CONTROL 	AND	QUALITY 	ASSURANCE	
Please refer to detailed Site Quality Management Plan and Manual of Procedures in the grant application 
appendix, which is maintained in the study records, for quality control and assurance protocols.  
 
13. ETHICS/PROTECTION 	OF	HUMAN	SUBJECTS 	
13.[ADDRESS_688713] 
the protocol and the protocol informed consent form(s) approved, as appropriate, by [CONTACT_132793] (IRB)/ethics committee (EC) and any other applicable regulatory entity (RE). Upon receiving final approval, sites will submit all required protocol registration documents to the DAIDS Protocol Registration Office (DAIDS PRO) at the Regulatory Support Center (RSC).  The DAIDS PRO will review the 
submitted protocol registration packet to ensure t hat all of the required documents have been received.    
 Site-specific informed consent forms (ICFs) WILL NOT be reviewed or approved by [CONTACT_68410], and 
sites will receive an Initial Registration Notification when the DAIDS PRO receives a complete registration 
packet.  Receipt of an Initial Registration Notification indicates successful completion of the protocol 
registration process. Sites will not receive any additional notifications from the DAIDS PRO for the initial 
protocol registration.  A copy of the Initial Registration Notification should be retained in the site's regulatory 
files.  Upon receiving final IRB/EC and any other applic able RE approval(s) for an amendment, sites should 
implement the amendment immediately.  Sites are r equired to submit an amendment registration packet to 
the DAIDS PRO at the RSC.  The DAIDS PRO will review the submitted protocol registration packet to ensure that all the required documents have been received. Site-specific ICF(s) WILL NOT be reviewed and 
approved by [CONTACT_530321] a complete registration packet. A copy of the Amendment Registration Notification 
should be retained in the site's regulatory files. 
 
For additional information on the protocol registration process and specific documents required for initial and amendment registrations, refer to the current version of the DAIDS Protocol Registration Manual. 
 
13.[ADDRESS_688714]	
The investigator will ensure that this study is conducted in full conformity with the current revision of the 
Declaration of Helsinki, or with the International Conference for Harmonization Good Clinical Practice (ICH-GCP) regulations and guidelines, whichever affords the greater protection to the subject. This protocol and associated informed consent documents must be revi ewed and approved by [CONTACT_530322].   
13.3 	Informed 	Consent	Process	
All participants participating in this study will be required to sign an IRB approved informed consent form.  Participants who enroll in any of the sub-studies will also sign an additional consent form specific to each applicable sub-study. Prior to signing the consent form(s ), the participants will meet with designated study 
staff who has been specially trained in obtaining informed consent.  The participant will review the consent form in detail with the designated study staff and have the chance to ask questions.  The study coordinator will then ask the participant questions to ensure that they understand the information presented in the consent form.  The rights and welfare of the participants will be protected by [CONTACT_530323] 6.6  
March 1, 2017 	 Page 45	
 quality of their medical care will not be adversely affected if they decline to participate in this study.  
Participants will be given time to consider the risks and benefits of participating.  A copy of the informed 
consent document will be given to the participants for their records.  The participants may withdraw consent at any time throughout the course of the trial.  Consent forms for HIV infected and HIV uninfected (control) 
participants are included in this application.  
13.4 Participant 	Confidentiality 	
A Certificate of Confidentiality will be obtained and all information that identifies study subjects will be 
handled in accordance with regulatory bodies including HIPAA regulations and the University of Minnesota’s IRB.  Information will be made available to the PI [INVESTIGATOR_530264].  In addition, information may be re viewed by [CONTACT_18121], the Office For Human Research 
Protections and the IRB.  Prior to screening, participants in this study will sign an authorization to use or disclose protected health information for research purposes.  All staff will have been trained in the use of protected health information.  Subjects will be assigned to a subject ID number and a link between identifiers will be maintained in a log.  This log will be kept in a locked cabinet in a secure office.  Only the PI 
[INVESTIGATOR_530265].   
 
13.5 Study	Discontinuation 		
After study completion or in the event that the study is discontinued, subjects will stop taking study agents (for the HIV group: losartan or placebo; for controls: Stribild and Prezista).  
 
14. DATA	 HANDLING 	AND	RECORD 	KEEPI[INVESTIGATOR_1645] 	
14.[ADDRESS_688715]. Schacker.
 Study data will be recorded in study progress notes.  Explanations will be mandated for any 
missing data.  Study records will be retained according to federal regulations. For further detailed description of data management please refer to the Manual of Procedures and Data Management Plan maintained in the study files.   
14.2 Source	documents 	and	Access	to	Source	Data	
In accordance with NIH policy we will make any source data accumulated as a result of this program available to others in a timely and reasonable fashion.  We will make data available at the time it is accepted for publication.  Written requests for access to data  before publication can be made to the administrative 
core and, if reasonable, data will be forwarded to the individual(s) requesting access. 
 
14.[ADDRESS_688716]. Schacker’s laboratory, [CONTACT_530339]’s laboratory, [CONTACT_530340]’s laboratory, [CONTACT_32253]’s laboratory, and [CONTACT_371392]’ laboratory will be entered into the database by [CONTACT_530324]. In addition, a written report of the data with a full accounting of how the data was generated, how much sample was used, and any unusual circumstances surrounding the generation of data (need for repeated experiments, reason 
for rejecting data from a data set, specimen handling pr oblems, etc.) will be sent on a monthly basis to 
designated study staff. They will place a copy of the wr itten report into the study chart of each individual 
Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV 
 
Protocol Version 6.[ADDRESS_688717] study charts to compare source documentation with data entered locally and at remote laboratories. Discrepancies will be resolved immediately. If an error rate of data entry of more than 3% is 
discovered for an individual or a laboratory, we will conduct a full audit of data from that person or that site.  
We prefer to have data entered by [CONTACT_530325] (as opposed to a data entry person working off faxed records) because we have found that data is available for discussion more rapi[INVESTIGATOR_530266] a more interactive research environment.  
 
 
15. PUBLICATION 	POLICY	
Publication of the results of this trial will be governed by [CONTACT_530326].  Any presentation, abstract, 
or manuscript will be made available for review by [CONTACT_530327].  
Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV 
 
Protocol Version 6.[ADDRESS_688718] Dis, 2008. 198(4): p. 
456-64. 
2. Mehandru, S., et al., Primary HIV-1 infection is associated with preferential depletion of CD4+ T 
lymphocytes from effector sites in the gastrointestinal tract.  J Exp Med, 2004. 200(6): p. 761-70. 
3. Talal, A.H., et al., Virologic and immunologic effect of antiretroviral therapy on HIV-[ADDRESS_688719], 2001. 26(1): p. 1-7. 
4. Guadalupe, M., et al., Severe CD4+ T-cell depletion in gut lymphoid tissue during primary human 
immunodeficiency virus type 1 infection and substantial delay in restoration following highly active 
antiretroviral therapy.  J Virol, 2003. 77(21): p. [ZIP_CODE]-17. 
5. Lange, C.G., et al., Nadir CD4+ T-cell count and numbers of CD28+ CD4+ T-cells predict functional 
responses to immunizations in chronic HIV-1 infection.  Aids, 2003. 17(14): p. 2015-23. 
6. Lange, C.G., et al., CD4+ T-lymphocyte nadir and the effect of highly active antiretroviral therapy on 
phenotypic and functional immune restoration in HIV-1 infection.  Clin Immunol, 2002. 102(2): p. 154-61. 
7. Rigaud, M., et al., Impaired immunity to recall antigens and neoantigens in severely immunocompromised 
children and adolescents during the first year of effective highly active antiretroviral therapy.  J Infect Dis, 
2008. 198(8): p. 1123-30. 
8. Vigano, A., et al., Humoral and cellular response to influenza vaccine in HIV-infected children with full 
viroimmunologic response to antiretroviral therapy.  J Acquir Immune Defic Syndr, 2008. 48(3): p. 289-
96. 
9. Lohse, N., et al., Survival of persons with and without HIV infection in Denmark, 1995-2005.  Annals of 
internal medicine, 2007. 146(2): p. 87-95. 
10. Deeks, S.G., E. Verdin, and J.M. McCune, Immunosenescence and HIV.  Curr Opin Immunol, 2012. 
11. Hunt, P.W., et al., T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency 
virus-infected patients with sustained viral suppression during antiretroviral therapy.  J Infect Dis, 2003. 
187(10): p. 1534-43. 
12. Jiang, W., et al., Plasma levels of bacterial DNA correlate with immune activation and the magnitude of 
immune restoration in persons with antiretroviral-treated HIV infection. J Infect Dis, 2009. 199(8): p. 
1177-85. 
13. Plaeger, S.F., et al., Immune activation in the pathogenesis of treated chronic HIV disease: a workshop 
summary. AIDS Res Hum Retroviruses, 2012. 28(5): p. 469-77. 
14. Hunt, P.W., et al., Valganciclovir reduces T cell activation in HIV-infected individuals with incomplete 
CD4+ T cell recovery on antiretroviral therapy.  J Infect Dis, 2011. 203(10): p. 1474-83. 
15. Brenchley, J.M., et al., Microbial translocation is a cause of systemic immune activation in chronic HIV 
infection. Nat Med, 2006. 12(12): p. 1365-71. 
16. Sandler, N.G., et al., Plasma levels of soluble CD14 independently predict mortality in HIV infection. J 
Infect Dis, 2011. 203(6): p. 780-90. 
17. Schacker, T.W., et al., Lymphatic tissue fibrosis is associated with reduced numbers of naive CD4+ T 
cells in human immunodeficiency virus type 1 infection.  Clin Vaccine Immunol, 2006. 13(5): p. [ADDRESS_688720], 2002. 110(8): p. 1133-9. 
19. Zeng, M., et al., Cumulative mechanisms of lymphoid tissue fibrosis and T cell depletion in HIV-[ADDRESS_688721], 2011. 121(3): p. 998-1008. 
20. Estes, J.D., et al., Premature induction of an immunosuppressive regulatory T cell response during acute 
simian immunodeficiency virus infection.  J Infect Dis, 2006. 193(5): p. 703-12. 
21. Estes, J.D., et al., Simian immunodeficiency virus-induced lym phatic tissue fibrosis is mediated by 
[CONTACT_530282] 1-positive regulatory T cells and begins in early infection.  J Infect Dis, 
2007. 195(4): p. 551-61. 
Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV 
 
Protocol Version 6.6  
March 1, 2017 	 Page 48	
 22. Schacker, T.W., et al., Amount of lymphatic tissue fibrosis in HIV infection predicts magnitude of HAART-
associated change in peripheral CD4 cell count.  Aids, 2005. 19 (18): p. 2169-71. 
23. Zeng, M., et al., Lymphoid tissue damage in HIV-1 infection depletes naive T cells and limits T cell 
reconstitution after antiretroviral therapy.  PLoS pathogens, 2012. 8(1): p. e1002437. 
24. Dummer, W., et al., Autologous regulation of naive T cell homeostasis within the T cell compartment. J 
Immunol, 2001. 166(4): p. 2460-8. 
25. Tan, J.T., et al., IL-7 is critical for homeostatic proliferation and survival of naive T cells.  Proc Natl Acad 
Sci U S A, 2001. 98(15): p. 8732-7. 
26. Rathmell, J.C., et al., IL-7 enhances the survival and maintains the size of naive T cells.  J Immunol, 2001. 
167(12): p. 6869-76. 
27. Shihab, F.S., et al., Pi[INVESTIGATOR_530267]-beta1 and matrix proteins 
and ameliorates fibrosis in chronic cyclosporine nephrotoxicity. Am J Transplant, 2002. 2(2): p. 111-9. 
28. Iyer, S.N., D.M. Hyde, and S.N. Giri, Anti-inflammatory effect of pi[INVESTIGATOR_530268]-hamster 
model of lung inflammation. Inflammation, 2000. 24(5): p. 477-91. 
29. Miric, G., et al., Reversal of cardiac and renal fibrosis by [CONTACT_21173][INVESTIGATOR_530269]-
diabetic rats.  Br J Pharmacol, 2001. 133(5): p. 687-94. 
30. Azuma, A., et al., Double-blind, placebo-controlled trial of pi[INVESTIGATOR_530270]. Am J Respir Crit Care Med, 2005. 171(9): p. 1040-7. 
31. Brook, N.R., et al., The experimental agent pi[INVESTIGATOR_530271]-fibrotic gene expression in a model of 
tacrolimus-induced nephrotoxicity. J Surg Res, 2005. 125(2): p. 137-43. 
32. Card, J.W., et al., Differential effects of pi[INVESTIGATOR_530272]-induced pulmonary toxicity. Toxicol Sci, 2003. 75(1): p. 169-80. 
33. Di Sario, A., et al., The anti-fibrotic effect of pi[INVESTIGATOR_530273]1(I), TIMP-1 and MMP-2.  Dig Liver Dis, 2004. 36(11): p. 744-51. 
34. Garcia, L., et al., Pi[INVESTIGATOR_530274]. J Hepatol, 2002. 37(6): p. 
797-805. 
 
35. Elbaz, M., et al., Losartan, a therapeutic candidate in congenital muscular dystrophy: studies in the dy(2J) 
/dy(2J) mouse. Ann Neurol, 2012. 71 (5): p. 699-708. 
36. Campi[INVESTIGATOR_216408], J.M., et al., Losartan decreases plasma levels of TGF-beta1 in transplant patients with chronic 
allograft nephropathy.  Kidney Int, 1999. 56(2): p. 714-9. 
37. Volpi[INVESTIGATOR_9384], R.A., et al., Effect of enalapril and losartan on the events that precede diabetic nephropathy in 
rats. Diabetes Metab Res Rev, 2003. 19(1): p. 43-51. 
38. Arnold, S.A., et al., Losartan slows pancreatic tumor progression and extends survival of SPARC-null 
mice by [CONTACT_530328].  PLoS ONE, 2012. 7(2): p. e31384. 
39. Boffa, J.J., e t al., Regression of renal vascular 
and glomerular fibrosis: role of angiotensin II receptor 
antagonism and matrix metalloproteinases.  J Am Soc Nephrol, 2003. 14(5): p. 1132-44. 
40. el-Agroudy, A.E., et al., Effect of angiotensin II receptor blocker on plasma levels of TGF-beta 1 and 
interstitial fibrosis in hypertensive kidney transplant patients.  Am J Nephrol, 2003. 23(5): p. 300-6. 
41. Mezzano, S.A., M. Ruiz-Ortega, and J. Egido, Angiotensin II and renal fibrosis.  Hypertension, 2001. 38(3 
Pt 2): p. 635-8. 
42. Lim, D.S., et al., Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of 
human hypertrophic cardiomyopathy.  Circulation, 2001. 103(6): p. 789-91. 
43. Diez, J., et al., Losartan-dependent regression of myocardial fibrosis is associated with reduction of left 
ventricular chamber stiffness in hypertensive patients.  Circulation, 2002. 105(21): p. 2512-7. 
44. Molina-Molina, M., et al., Losartan attenuates bleomycin induced lung fibrosis by [CONTACT_57026] 
E2 synthesis.  Thorax, 2006. 61(7): p. 604-10. 
45. Masutomo, K., N. Makino, and M.S. Fushiki, Effects of losartan on the collagen degradative enzymes in 
hypertrophic and congestive types of cardiomyopathic hamsters.  Mol Cell Biochem, 2001. 224(1-2): p. 
19-27. 
46. Guo, L., et al., Angiotensin II induces interleukin-6 synthesis in osteoblasts through ERK1/[ADDRESS_688722] via 
AT1 receptor.  Arch Oral Biol, 2011. 56 (3): p. 205-11. 
Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV 
 
Protocol Version 6.6  
March 1, 2017 	 Page 49	
 47. Han, C., et al., Angiotensin II induces C-reactive protein expression through ERK1/2 and JNK signaling in 
human aortic endothelial cells.  Atherosclerosis, 2010. 212(1): p. 206-12. 
48. Radonic, T., et al., Losartan therapy in adults with Marfan syndrome: study protocol of the multi-center   
randomized controlled COMPARE trial. Trials. 11: p. 3. 
49. Einstein, M.H., et al., Comparison of the immunogenicity and safety of Cervarix and Gardasil human 
papi[INVESTIGATOR_28597] (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum Vaccin, 2009. 
5(10): p. 705-19. 
50. Einstein, M.H., et al., Comparative immunogenicity and safety of human papi[INVESTIGATOR_28597] (HPV)-16/18 
vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of 
healthy women aged 18-45 years. Hum Vaccin. 7(12): p. 1343-58. 
51. Einstein, M.H., et al., Comparison of the immunogenicity of the human papi[INVESTIGATOR_28597] (HPV)-16/18 
vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in 
healthy women aged 18-45 years. Hum Vaccin. 7(12): p. 1359-73. 
52. Hariri, S., et al., Prevalence of genital human papi[INVESTIGATOR_360733], the 
National Health And Nutrition Examination Su rvey, 2003-2006. J Infect Dis. 204(4): p. 566-73. 
53. Dunne, E.F., et al., Human papi[INVESTIGATOR_28597] (HPV) 6, 11, 16, and 18 prevalence among females in the 
[LOCATION_002]--National Health And Nutrition Ex amination Survey, 2003-2006: opportunity to measure 
HPV vaccine impact? J Infect Dis. 204(4): p. 562-5. 
54. Markowitz, L.E., et al., Seroprevalence of human papi[INVESTIGATOR_406980] 6, 11, 16, and 18 in the United 
States: National Health and Nutrition Examination Survey 2003-2004. J Infect Dis, 2009. 200(7): p. 1059-
67. 
 
   
  
Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV 
 
Protocol Version 6.[ADDRESS_688723] and novel contrasts and their parametric maps to assess lymph flow and 
collagen amounts in LT. MRI studies will be performed on a 3 Tesla and/or 7T imaging systems (Siemens 
Medical Solutions, Erlangen, [LOCATION_013]). To acquire data, surface or surface array coils will be used for signal 
reception.   Protocol: 1) Scout imaging to localize target anatomy. (1 minute) 2) Maps of B1+ by [CONTACT_941] 3D AFI technique (4 minutes) 
3) T2 weighted imaging (turbo spin echo, 0.5x0.5x3.0 mm3 resolution in the three planes) (10 minutes) 
4) T2 mappi[INVESTIGATOR_530275]. (5 minutes) 5) T1 mappi[INVESTIGATOR_530276] (72) (5 minutes) 6) Diffusion weighted imaging (DWI), using a standard single shot approach in three orthogonal directions with multiple diffusion encoding b-values (e.g. 0, 50, 400 and 800 s/mm2) allowing the calculation of ADC– how 
long? (5 minutes) 
7) Magnetization transfer (MT) using GRE readout, with T1sat mappi[INVESTIGATOR_007] (10 minutes) 8) T1ρ mappi[INVESTIGATOR_007], using GRE readout (not clear, the application mention them, but then does not give 
details)  (5 minutes) 9) T2ρ mappi[INVESTIGATOR_007], using GRE readout (not clear, the application mentions them, but then does not give 
details) (5 minutes) 
10) RAFFn mappi[INVESTIGATOR_530277] (10 minutes)  
 Inclusion Criteria:   (See Section 5.2) Same as parent losartan study.  
Exclusion Criteria: 
 Exclusion criteria will be assessed during a safety screening interview and during final consent.  A questionnaire will be provided regarding general health and exclusion/inclusion criteria.  The investigator doing the interview will determine if any of the exclusion criteria apply.  Subjects will be asked: 
1) To describe any previous surgeries to help subjects and study staff open a dialogue as to any possible 
contraindications listed in the yes/no section below. 2) If they are claustrophobic and to rate the severity. 3) If they wear hearing aids and if they can be removed for the scan. 4) If they have a transdermal delivery system, and if yes where is it located and if it can be removed for the 
study. 
5) If they wear colored contact [CONTACT_240357],  if yes, can they be removed for the study. 
6) To provide a list of medications, dosages and ti me of last dose for medicines taken regularly. 
Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV 
 
Protocol Version 6.6  
March 1, 2017 	 Page 51	
 7) To identify if they have any pre-existing medi cal conditions including Hypertension, Hypotension, 
Diabetes, Cardiovascular Disease and Fever. 
8) To identify if they ever had an operation. 9) To indicate if they have ever been injured by a metallic foreign body which was never removed. 
10) If they wear braces and/or if they have removabl e bridgework, false teetch or a permanent retainer. 
11) If they have any tattoos, non-removabl e body pi[INVESTIGATOR_530278]. 
12) If they are currently using/wearing an IUD or diaphragm. 13) If they have any reason to believe they are pregnant.  (If the subjects are unsure about their pregnancy status, test kits will be available to subjects). 
 
In addition, a set of yes/no questions will be asked in the screening form for the participant to confirm or deny the presence of items that may be hazardous to their safety and/or some interfere with the MRI examination, including:   Yes  No Cardiac pacemaker 
 Yes  No Implanted cardiac defibrillator 
 Yes  No Carotid artery vascular clamp  Yes  No Intravascular stents, filters, or coils  Yes  No Aortic clip  Yes  No Internal pacing wires 
 Yes  No Vascular access port and/or catheter 
 Yes  No Swan-Ganz catheter  Yes  No Shunt (spi[INVESTIGATOR_55442])  Yes  No Aneurysm clip(s)  Yes  No Neurostimulator  Yes  No Electrodes (on body, head, or brain) 
 Yes  No Heart valve prosthesis 
 Yes  No Any type of prosthesis (eye, penile, etc.)  Yes  No Artificial limb or joint replacement  Yes  No Bone growth/fusion stimulator  Yes  No Bone/joint pin, screw, nail, wire, plate 
 Yes  No Metal rods in bones 
 Yes  No Harrington rods (spi[INVESTIGATOR_050])  Yes  No Metal or wire mesh implants  Yes  No Wire sutures or surgical staples  Yes  No Insulin pump or infusion device 
 Yes  No Any metal fragments (i.e. metal shop) 
 Yes  No Any implant held in place by a magnet  Yes  No Cochlear, otologic, or ear implant     
RISKS AND BENEFITS:   
 NOTE: Appendix F’s for both 3T and 7T systems are on file at the IRB and will not need to be submitted with this addendum.  
Other Potential Risks. 
 1) Magnetic Field in the MRI (subject environment) 2) Metallic objects carried into the MRI room 3) Other energies, such as radiofrequency pulses, or rapid changes in the field strength 
Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV 
 
Protocol Version 6.6  
March 1, 2017 	 Page 52	
 4) Displacement of Implanted metallic devices 
5) Acoustic noise   Any risks from high magnetic field strength that has been identified as a concern by [CONTACT_1622]'s office of device 
evaluation, has been addressed by [CONTACT_379047], who performed numerous animal experiments. The results 
indicate non-significant risks (either short term or long term) at these magnetic field strengths (3T/7T).  Data over the last 10+ years indicate that the 7 Tesla magnetic field does not pose a significant risk to human volunteers. Metallic objects that are entered into the magnetic field can accelerate into the magnet potentially 
causing damage to the magnet or persons in the magnet room.  
 In addition, implanted metallic objects can be displaced. The acoustic noise generated by [CONTACT_530329] a person's hearing.   Finally, radiofrequency pulses impart small amounts of energy into the subject, and needs to be monitored by 
[CONTACT_530330].   Most people experience no ill effects from the strong magnetic field, but some people report dizziness, mild nausea, headache, a metallic taste in their mouth, or sensations of flashing lights. These symptoms, if present, 
subside shortly after leaving the magnet. No serious ill effects have been reported to date at any site operating 
at 7T. If any sensations experienced cause discomfort or pain, informing the researcher will terminate the ongoing study and the subject will be taken out of the magnetic field.  The risk of metallic objects being carried into the magnet room by [CONTACT_530331] (keys, hair pi[INVESTIGATOR_2115], coins, glasses, watches, etc. ) for secure storage 
in a locker provided to them, prior to entering the magnet room.  
 All risk of other energies involved in MRI imaging are controlled such that they are not a significant risk and are substantially equivalent to clinical MRI systems, such as the Philips and Siemens devices currently in use at the University of Minnesota Medical Center, Fairview. These factors are in compliance with FDA guidelines. 
  In addition, there are safety monitors in the MRI instrument that will prevent the machine from running if these energies exceed the FDA levels. Risks posed to persons with implanted devices are avoided by [CONTACT_530332]. Any unknown risks posed to fetuses are avoided by [CONTACT_530333].  
Acoustic noise is reduced to FDA acceptable levels by  [CONTACT_530334], providing padding 
around the subject ears, and by [CONTACT_530335]. The acoustic 
noise has been carefully measured using a special probe inside the magnet.    MRI scans have become a routine diagnostic tool widely us ed in medicine. Based on more than two decades of 
experience with this technique, appropriate guidelines exist for its use to minimize the risks of the study. 
Although there is no direct benefit to the research subjects, the parameters and research data garnered from 
the studies will lead to being able to make much improved clinical and diagnostic decisions. With minimal risk to the subjects, this research and the MRI instruments will allow us to obtain improved anatomic and functional throughout the human body. Twenty years of research at [ADDRESS_688724] benefits to the individuals participating in this study as subjects.  However, the new methods under development may provide novel biomarkers for m onitoring disease progression and treatment response, 
aid in the development and evaluation of novel interventions, and/or provide unique tools to aid in the diagnosis and prognosis of disease. 
Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV 
 
Protocol Version 6.6  
March 1, 2017 	 Page 53	
  
  INFORMED CONSENT PROCESS: 
 
Upon arrival at the CMRR, the subject will be greeted by [CONTACT_3647], provided the consent and MRI safety screening forms and given a brief description of the study that  will be conducted that day.  Specific details of the 
study which will be reviewed including:  - the field strength of the study (3T or 7T) 
- the region of the body that will be studied 
- the RF coils that will be used - any additional hardware such as ECG leads or respi[INVESTIGATOR_530279] - any particular tasks that they may be asked to perform such as breath holding during the MRI procedure.  
After this introduction the subject will then be given an opportunity to read the consent form and ask questions.  
The researcher will provide the participant ample time to decide whether or not to participate. The researcher 
will also assess whether the participant understands the study’s procedures and will stress the voluntary nature of the experiment. In addition, the subject will be reminded that this is purely a research study and that the data acquired cannot be used in place of standard imaging obtained through their physician. 
 
 Volunteers will be given the study specific consent form upon arriving at the CMRR at which time the 
investigator will detail the specific goals for the study that day and provide any study specific instructions.    The investigator will give the participant ample time to review the informed consent document. This may entail 
waiting with the subject while they review the material or leaving the room if they need more time to consider 
the study. When the participant has finished reading the doc ument and signs (or chooses not to sign) it, they 
will notify the researcher. Participant questions will be answered prior to their consenting.  One of the investigators listed on the protocol will obtain informed consent. Usually it will be the individual who 
will be performing the MRI scan.  
Gregory J. Metzger – Associate Professor – already trained and running similar studies Silivia Mangia – Associate Professor – al ready trained and running similar studies  
Shalom Michaeli – Associate Professor – already trained and running similar studies Diane Hutter – Research Nurse – already trained and consenting on similar protocols 
 
The subject will always provide the informed consent or the study will not be performed. 
 As described above, the investigator(s) will give the participant ample time to review the informed consent document. This may entail leaving the room if they need more time to consider the study reducing any pressure to sign it. Subjects are also instructed that they may terminate participation at any time without prejudice.  
 